

























The Dissertation Committee for Jin Seo certifies 
 


































Philip W. Tucker 
 











Presented to the Faculty of the Graduate School of 
the University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
DOCTOR OF PHILOSOPHY 
 










 I would like to thank my mentor, Dr. Jaquelin P. Dudley, for her constant 
support and guidance.  I would also like to thank the members of my dissertation 
committee, Dr. Henry R. Bose, Jr., Dr. Jon Huibregtse, Dr. David G. Johnson, and Dr. 
Philip W. Tucker for their comments, suggestions, and encouragement. 
  I would like to thank all current and previous Dudley lab members; Sanchita, 
Dana, Hong, Keqin, Jinqi, Mary, Urmila, Melissa, Jenny, Rachel, Farah, and Quan for 
sharing protocols and ideas.  I would like to especially thank Mary who has worked with 
me and critically read my dissertation.   
 I would like to thank Insuk, Jungseog, Hyungseog, Velu, John, Dongkyoon, 
Shwetal, Hongbo, Andy, Hui, Sangwook, BaeckSeung, Jihoon, Jonghwan, Will, 
George, and Helen who helped me with my work and made my graduate life more 
enjoyable. 
 I acknowledge with love my wife who trusted me, my work and my vision, our 
son who brings us pure joy, my father who has called daily to show his support and 
encouragement, my mother who has prayed for me at the dawn service everyday, my 
brother who studied biology and can appreciate my work, my sister who regularly sent 
various Japanese chocolates and cookies with great love, and my parents-in-law who 
visited several times to help and encourage me. 
The graduate school years were not only a great journey in training as an 
independent scientist but also a time to learn to feel God who is always with me and 





THE NUCLEAR MATRIX AFFECTS SATB1-MEDIATED MMTV SUPPRESSION 
 
Publication No. ________ 
 
 
Jin Seo, Ph.D. 
The University of Texas at Austin, 2005 
 
Supervisor: Jaquelin P. Dudley 
 
Mouse mammary tumor virus (MMTV) is a betaretrovirus that causes mammary 
adenocarcinomas in susceptible mouse strains.  Milk-borne MMTV initially causes a 
low level infection of gut-associated lymphoid cells, which then deliver the virus to 
mammary epithelial cells, a target for high levels of MMTV replication and insertional 
mutagenesis.  Although wild-type MMTV is not lymphomagenic, variants that cause 
thymic lymphomas have alterations in the long terminal repeat (LTR), including a 
deletion of negative regulatory elements (NREs).  This deleted region contains binding 
sites for at least two cellular proteins, CCAAT displacement protein (CDP) and special 
AT-rich binding protein 1 (SATB1).  SATB1 is expressed primarily in the thymus and 
has been proposed to suppress MMTV expression and integration in lymphoid tissues. 
Because of previous difficulties with SATB1 overexpression in culture, a 
transcriptional assay system for SATB1 function was developed.  Rat fibroblasts or 
mouse mammary cells, which express little SATB1, were stably transfected with 
 
vii
MMTV-luciferase reporter genes.  Transduction with retroviruses expressing wild-type 
SATB1 suppressed MMTV LTR expression.  SATB1 transduction also suppressed 
expression of integrated MMTV proviruses in rat cells, consistent with the primarily 
repressor function of this transcription factor.  
To delineate domains responsible for DNA binding and suppression of MMTV 
transcription in this system, SATB1 mutants were generated.  SATB1 is known to bind 
to the nuclear matrix, which has been shown to play important roles in transcription.  A 
nuclear matrix targeting sequence (NMTS) of SATB1 was identified as a 55-amino acid 
region between the dimerization domain and the major DNA-binding domain.  Both the 
DNA-binding and dimerization domains were necessary for binding to the MMTV NRE 
using gel shift assays, but the NMTS was not.  Deletion of the DNA-binding domain or 
the NMTS significantly alleviated repression of stably integrated MMTV LTR-reporter 
genes, confirming the importance of both DNA binding and nuclear matrix binding for 
SATB1-mediated MMTV suppression.  Additionally, cellular factors interacting with this 
SATB1 NMTS were identified through screening of a human thymic cDNA library using 
the yeast two-hybrid system.  Further studies using this reporter system for SATB1 
function and identification of protein interactions with the nuclear matrix should provide 
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  1  
1. INTRODUCTION 
1.1 MOUSE MAMMARY TUMOR VIRUS (MMTV) 
1.1.1 Classification 
The mouse mammary tumor virus (MMTV) was first identified in the 1930s as a 
causative agent of a high incidence of breast cancer in certain inbred mouse strains.  
MMTV is the prototype species of the genus Betaretrovirus within the family 
Retroviridae.  The morphology of the virion core originally was used for 
subclassification within the family Retroviridae, and MMTV was classified as a B-type 
virus characterized by a round, but eccentrically positioned, inner core.  There are two 
types of MMTV: exogenous MMTVs (milk-borne strains) and endogenous MMTVs.  
Exogenous MMTV strains are often named after the inbred mouse strain from which 
they were derived, for example, C3H MMTV or MMTV (C3H).  Endogenous MMTV 
proviruses are specified as Mtv followed by a number, for example, Mtv8 (57,159). 
      
1.1.2 Virion structure and genome structure  
Retroviruses contain two identical copies of a single-stranded RNA.  The 
genome is encapsidated by NC protein as a helical ribonucleoprotein (RNP) and is 
surrounded by CA proteins to make an icosahedral capsid.  The capsid is attached to 
the envelope by the MA protein.  Viral envelope is derived from the cellular plasma 
membrane and is embedded with a transmembrane (TM) protein and a surface (SU) 
protein.  Within the internal core, there are a few molecules of virally coded, RNA-
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dependent DNA polymerase (reverse transcriptase) and cellular tRNAs that are used 
as primers for reverse transcriptase. 
The ends of the viral genomic RNA contain short direct repeats (R), which flank 
the virally encoded genes, gag, dut, pro, pol, env, rem, and sag, as well as non-coding 
sequences comprising unique sequences at the 5’ (U5) and 3’ (U3) ends of the 
genome (57) (Fig.1).  The primer-binding site (PBS) is located just downstream of U5 
and is used for binding of the cellular tRNA that primes negative-strand DNA synthesis 
by reverse transcriptase.  The PBS is followed by the gag gene, which encodes MA, 
p21, CA, and NC (5’ to 3’), the nonglycosylated internal structural proteins. The gag 
gene is followed by coding sequences for the dut and pro genes that encode a 
dUTPase and protease, respectively.  The pol gene encodes RNase H, reverse 
transcriptase (RT), and integrase (IN), whereas env encodes the envelope proteins, 
SU and TM. Interestingly, another gene, rem, has been discovered with the env coding 
sequences.  The rem gene appears to encode an RNA export protein (M. Mann and J. 
Mertz, manuscript in preparation). MMTV is one of the few retroviruses that encode a 
gene within the U3 region (164).  The sag gene encodes a protein that is critical for 




























Fig.1. Diagram of MMTV RNAs from LTR. 
Integrated MMTV proviruses transcribe RNAs from the 5’ LTR promoter.  The 
RNA is spliced to make env, rem, and sag mRNAs using the splice donor (SD) and 
splice acceptor (SA) sites.  Functional sag mRNAs are made from the env promoter 
(146).  Arrows show the direction of transcription.  Thick dotted lines indicate the exons 
and V-shaped thin dotted lines indicate the regions removed by splicing. [This figure is 
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1.1.3 The MMTV life cycle 
Exogenous MMTV is transmitted to newborn pups through mother’s milk, 
whereas endogenous virus is transmitted by germline cells.  The virus in milk must 
traffic through the gut of newborn pups to the mammary epithelial cells, the final target 
for MMTV infection (Fig. 2).  MMTV uses lymphoid cells whose mobility allows 
distribution of the virus among various tissues.  The virus present in the gut crosses M 
cells and infects B cells in the Peyer’s patches of the gut.  The B cells are activated 
and present virally encoded superantigen (Sag) associated with MHC class II protein at 
the cell surface.   Interactions with specific Vβ chains of T-cell receptors activate the T 
cells to produce cytokines, which subsequently activate bystander cells to divide.  
These dividing cells are infected by MMTV and serve as a reservoir of infection for 











































Fig. 2. Life cycle of milk-borne MMTV. 
Newborn pups ingest milk containing MMTV from infected mothers.  The virus 
passes through M cells in the gut prior to infection of B and T cells.  The infected B 
cells present virally encoded superantigen (Sag) in conjunction with MHC class II 
protein at the cell surface.  Sag presentation allows interaction with specific T-cell 
receptors to activate T cells that subsequently produce cytokines.  These cytokines 
induce the division of bystander lymphoid cells that become infected by MMTV. 
Infected B and T cells are required to transfer virus to the mammary glands, the final 
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1.1.4 Virus attachment and entry into host cells 
The binding of the envelope protein (Env) to cellular surface receptor(s) is the 
first step of viral infection.  All mouse tissues bind to MMTV envelope protein, SU, 
although the binding affinity is different among tissues.  Binding is highest in the 
mammary gland and spleen, intermediate in the ovary and salivary gland, and lowest in 
the liver and adrenal glands (11).   
To identify the MMTV receptor, hybrids between Chinese hamster cells and 
mouse tumor cells were developed.  These hybrid cell lines were infected with 
pseudotypes of vesicular stomatitis virus (VSV) containing MMTV envelope protein.  
After infection, analysis of the segregated mouse chromosomes in the mouse-hamster 
hybrids mapped this MMTV receptor (Mtvr1) to mouse chromosome 16 (85).  A second 
cellular receptor for MMTV (Mtvr2) was identified as a novel transmembrane protein on 
the proximal end of chromosome 19 using a cDNA expression library (75).  The 
discrepancy suggests that MMTV may have more than one receptor or a co-receptor 
for attachment and entry into susceptible cells.  Most recently, the identity of Mtvr1 was 
revealed to be the transferrin receptor (Tfrc), which is located on mouse chromosome 
16 at 21.2 cM (178).  The transferrin receptor is ubiquitously expressed on all rodent 
cells, and its ability to be recycled to the cell surface explains the lack of superinfection 
resistance observed with MMTV, but not many other retroviruses (61,178).  
 
1.1.5 Virus replication 
Retroviral replication is initiated by the reverse transcription of the single-
stranded viral RNA genome into a double-stranded DNA copy.  The DNA is 
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subsequently integrated into the host cell chromosomal DNA mediated by virally 
encoded integrase (211).  RT synthesizes a minus-strand DNA from plus-stranded viral 
RNA using its RNA-dependent DNA polymerase activity.  The RNA portion of the RNA-
DNA hybrid is degraded through the RNase H activity.  RT then synthesizes a plus-
strand DNA using the minus-strand DNA template, its DNA-dependent DNA 
polymerase activity, and RNA primers derived from the degraded plus-stranded RNA.  
The resulting double-stranded DNA or provirus forms viral nucleoprotein complexes 
associated with IN, which is required for integration (57).  The nucleoprotein complexes 
associate with cellular chromosomes when the nuclear membrane breaks down during 
cell division.  IN removes a dinucleotide from the ends of proviral DNA to produce 3’-
OH recessed LTRs.  The two recessed ends are integrated into host chromosomal 
DNA by a concerted mechanism in which both viral DNA ends attach to sites on 
opposite strands of the target DNA.  However, like other retroviruses, MMTV 
integration occurs at many sites in the cellular DNA (57).   
The integrated provirus contains many regulatory cis-acting elements within the 
LTR, including binding sites for RNA polymerase II.  Transcription by RNA pol II starts 
at the U3/R junction within the 5’ LTR and terminates at the R/U5 junction within the 3’ 
LTR.  Transcripts are capped and polyadenylated by cellular enzymes in the nucleus.  
Some portions of the full-length transcripts are transported into the cytoplasm without 
splicing for translation of the Gag and Pol proteins or are packaged into new virus 
particles.  Other transcripts are spliced to generate the singly spliced env and sag 
mRNAs or the doubly spliced rem mRNA. 
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1.1.6 Transcriptional regulation 
1.1.6.1 Hormone-responsive element (HRE) 
MMTV transcription is elevated 10- to 50-fold when infected cells are grown in 
the presence of glucocorticoids or other specific steroid hormones, such as 
progesterone and testosterone (174).  Four binding sites for ligand-bound hormone 
receptors reside in the hormone-responsive elements (HREs) between –200 and –50 
relative to the transcription initiation site in the MMTV LTR (91,114,161,181,181,206).  
Sequence analysis of these regions showed that the hexanucleotide 5’-TGTTCT-3’ 
represents receptor binding sequences (181).  Hormonal induction is achieved by the 
loading of transcription factors, including NF1, OCT1 (OTF1), and TFIID downstream of 
the HRE in the MMTV LTR (200), subsequent to the transient interaction of ligand-
bound steroid receptors with their binding sites (7,82).   
Ligand-dependent transcriptional activation by nuclear receptors is achieved by 
recruitment of complex co-regulators on the promoters of hormone-regulated genes 
(113).  These receptors directly interact with general transcription factors (GTFs), such 
as TATA-binding protein (TBP) and TBP-associated factor (TAFII110), a subunit of 
TFIID, to initiate transcription (182,183).  However, stimulation of reporter gene 
transcription by the progesterone receptor is inhibited by co-expression of the estrogen 
receptor (138).  The result indicates that there is competition between nuclear 
receptors and limited transcription factor(s).  However, the transcriptional squelching 
between receptors cannot be explained solely by the direct interaction between nuclear 
receptors and GTFs.  A search for nuclear receptor co-activators revealed two groups 
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of co-activators, known as p300/CREB-binding protein (CBP) and the mammalian 
Mediator complexes (TRAP, DRIP, ARC, etc.) (24,169). 
Interactions between p300/CBP and the nuclear receptors can occur directly or  
indirectly through members of the steroid receptor coactivator (SRC) family, such as 
SRC-1, TIF2/GRIP1, and RAC3/ACTR/pCIP/AIB-1 (33,119).  Nuclear receptor 
interactions with p300/CBP are necessary for their transactivation function (1,33,100).  
p300 and CBP are large nuclear proteins, which have been demonstrated to interact 
with many transcription factors, including CREB, AP1, NF-κB, and SATB1, as well as 
general transcription factors, such as TFIIB and TBP (66,76,96,163).  Therefore, 
p300/CBP proteins link components of the basal transcription machinery and specific 
DNA-binding transcription factors.  Moreover, these co-activators have intrinsic histone 
acetyltransferase (HAT) activity (156).  This observation implies that p300/CBP may 
contribute directly to transcriptional regulation via targeted acetylation of chromatin as 
well as by serving as a simple adapter between transcription factors and p300/CBP-
associated factor (P/CAF) or GTFs (217). 
Mediator first was identified in yeast as a complex that was associated with 
RNA Pol II and required for transcriptional activation in vitro (147).  The metazoan 
versions of yeast Mediator are central and necessary components for transcriptional 
activation by many transcription factors (169).  Thyroid hormone receptor-associated 
protein (TRAP) and Vitamin-D-receptor interacting protein (DRIP) complexes were 
identified as human Mediators that interact with nuclear receptors (93,170).  The 
mammalian Mediator complexes are required for activator-responsive transcription and 
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usually consist of heteromeric complexes containing from 7 to 25 distinct polypeptides 
(24,169).   
  
1.1.6.2 Negative regulatory elements (NREs) 
Nucleotide sequences of proviruses acquired in MMTV-induced mouse T-cell 
lymphomas showed 400 to 500 bp deletions in the U3 region (located from ca. -655 to 
–165).  Furthermore, an MMTV LTR-reporter gene carrying an NRE deletion exhibited 
higher transcriptional activity in mink lung cells than that of wild-type LTRs, suggesting 
that the deleted region contains NREs (58,89).  Mice carrying MMTV LTR-reporter 
plasmids with NRE deletions showed expression in novel sites, such as the heart, 
brain, and skeletal muscle, where endogenous MMTVs and the full-length LTR are not 
expressed (177).  Thus, negative elements in the MMTV LTR suppress viral 
transcription in many different tissues.   
To further map the sequences responsible for tissue-specific transcriptional 
suppression, a series of deletion mutants were prepared in the LTR region between -
634 to -158.   Experimental results using these mutants verified that there are two 
negative elements: one in the region from -484 to -426 designated the promoter-distal 
NRE, and one in the region between -281 to -255 designated promoter-proximal NRE 
(25).  Gel shift assays showed that two high-molecular-mass complexes bound to both 
NREs, and these complexes were termed upper or ubiquitous-binding protein (UBP) 
and NRE-binding protein (NBP).  Protein purification experiments and gel shift/antibody 
ablation assays identified special AT-rich binding protein 1 (SATB1) as NBP and 
CCAAT displacement protein (CDP) as UBP (124).  Mice carrying an MMTV LTR-
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reporter gene with a SATB1-binding site mutation (a 7-nt substitution mutation from -
272 to -265) showed an altered tissue-specific distribution of MMTV expression.  A 
dramatic increase in transcription was observed from mutant LTRs in lymphoid tissues 
where MMTV expression is normally suppressed, relative to mammary tissue, which 
normally shows the highest MMTV expression (25,124).   
The MMTV LTR has multiple CDP-binding sites, and overexpression of CDP 
decreased MMTV LTR-reporter gene expression in transient transfection assays.  
Mutations of CDP-binding sites in the LTR alleviated suppression of MMTV 
transcription in both stable and transient transfections, and wild-type CDP suppressed 
MMTV-reporter gene expression in the presence or absence of dexamethasone (DEX) 
(226,227).  Furthermore, CDP and SATB1 are both homeodomain proteins that are 
members of the Cut repeat family (123).  These proteins appear to interact with each 
other to regulate binding of each protein to the MMTV NRE.  Overexpression of CDP in 
Jurkat T cells that express high levels of SATB1 was able to elevate expression of a 
co-transfected MMTV LTR-reporter plasmid (123).   These results suggest that tissue-
specific MMTV expression may be partially controlled by the levels of two different 
repressors, CDP and SATB1 (123).   
 
1.1.6.3 Mammary gland enhancer element 
Mice expressing an MMTV LTR-myc transgene developed breast tumors at an 
accelerated rate, suggesting that LTR directly influences mammary-specific 
transcription (193).  MMTV LTR transgenes lacking sequences between -863 and -110 
showed tissue-specific expression similar to that of the full-length MMTV LTR, 
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suggesting that the 5’ end of the LTR is important to direct transcription in breast 
tissues (192).  A fragment of the MMTV LTR from -1166 to -987 was fused to a 
chloramphenicol acetyltransferase (CAT)-reporter gene and used to generate 
transgenic mice.  These transgenic mice showed elevated CAT activity in both 
mammary and salivary gland, suggesting that this LTR region acts as an enhancer of 
transcription in these tissues (142).  In transfection experiments, the region of the 
MMTV LTR from -1075 to -978 proved to be 5-fold more active in a mammary cell line 
(34i) than in NIH3T3 fibroblasts (136).  Furthermore, six cis-acting elements in this 
enhancer were identified, and multifactor complexes, such as mp5/AP-2 and NF-
1/CTF, bound to these elements to control enhancer activity (117,136).  Stat5 or 
related proteins bind near +520 (-675) on the MMTV LTR (195).  Stat5a- or Stat5b-
knockout mice showed reduced MMTV expression in mammary glands, but not in 
lymphoid tissues, demonstrating that this transcription factor family also is important for 
mammary-specific transcription (168). 
 
1.1.6.4 Chromatin remodeling in the MMTV LTR 
Eukaryotic DNA is compacted into chromatin affecting the accessibility of DNA-
binding proteins (7).  The basic unit of chromatin, the nucleosome, is formed by core 
histones with a (H3-H4)2 tetramer flanked by two H2A/H2B dimers (127).  A well-
characterized nucleosomal structure has been observed on the integrated MMTV LTR 
(173), which has been studied using cell lines containing bovine papillomavirus (BPV) 
episomes carrying the MMTV LTR.  Nuclei from cells carrying the MMTV LTR on BPV 
episomes were digested with micrococcal nuclease or with the chemical MPE-Fe(II) to 
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study nucleosome positioning.  The two digestion methods showed the same cleavage 
pattern, which differed from that of the naked MMTV LTR.  Cleavage sites were 
localized at +136, -60, -250, -444, -651, -826, and -1019 relative to the transcriptional 
initiation site with spacing of ca. 180 to 200 bp, consistent with nucleosomes (Fig. 3).  
Furthermore, in the presence of a synthetic glucocorticoid hormone, dexamethasone, 
the cleavage sites were not altered except for the region between -60 and -250 
containing the HRE (173).   
The synergistic binding of glucocorticoid receptor (GR) and transcription factors 
to the MMTV LTR has been well studied.  Nuclear factor 1/CCAAT-transcription factor 
(NF1/CTF) and GR bind to one of the nucleosomes (Nuc-B) in the MMTV LTR (47).  
The activation of the MMTV promoter by GR is thought to be a bimodal process based 
on experiments with both stable and transient templates.  NF1 was excluded from its 
binding site on stably transfected MMTV promoter without glucocorticoid treatment.  
However, the transcription factor constitutively binds to the transiently transfected 
MMTV reporter in the absence of hormones, suggesting that the naked template is 
more accessible to transcription factor binding.  The bimodal model involves (i) GR-
dependent structural transition of the chromatin, which leads to NF1/CTF loading, and 
(ii) GR-mediated recruitment of other transcription factors.  In this model, NF1 acts as 
an amplifier of the activation process (7).  
The MMTV LTR promoter isolated in low-salt nuclear extracts showed three 
distinct forms: the transcriptionally inactive promoter, the basally active promoter, and 
the fully activated promoter.  The inactive promoter contained TBP and histone H1. In 
contrast, the basally active promoter was bound by RNA pol II, TBP, Oct1, and 
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acetylated H3 in the absence of H1.  The hormone-activated promoter contains BRG1, 
the catalytic subunit of the SWI/SNF remodeling complex, as well as the factors bound 
to the basally active promoter.  All three forms condense into higher-order chromatin 
structures in vitro in the presence of Mg2+.  This suggests that the MMTV LTR promoter 
retains the ability to form the secondary/tertiary structure regardless of the binding of 






































Fig. 3. The nucleosomal structure of the MMTV LTR. 
The MMTV LTR is organized into a discrete nucleosomal structure.  The top 
figure shows the proviral structure while the bottom figure shows the detailed 
nucleosome structure in the LTR.  The LTR is shown as a box in the top diagram.  
Each nucleosome is shown as an oval and labeled Nuc-A to Nuc-F from the 3’ to the 5’ 
ends of the LTR.  The numbers depict the position of each nucleotide relative to the 
first nucleotide of the LTR.  The numbers in parentheses indicate the position of 
nucleotides relative to the transcription start site at the U3/R junction.  Nucleosomes 
are positioned as follows: Nuc-A, +1159 to +1304; Nuc-B +973 to 1119; Nuc-C, +787 
to +933; Nuc-D, +601 to +747; Nuc-E, +415 to +561; and Nuc-F, +229 to +375.  The 
transcription start site, U5, R, U3 regions are also shown in the detailed nucleosome 
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1.1.7 Viral genetics 
MMTV transmission occurs horizontally through exogenous (milk-borne) viruses 
and vertically through endogenous viruses.  More than 30 germline-associated MMTV 
loci (Mtv) have been identified, and most mouse strains genetically transmit two to 
eight distinct Mtvs.  However, the mammary tumor incidence of mice is primarily 
determined by transmission of virulent strains of milk-borne virus. The high-mammary 
cancer-incidence strain, C3H, has a 90% tumor incidence, while the BALB/c strain has 
a low-mammary-tumor incidence of 1% or less, yet both strains carry three or more 
endogenous Mtvs.  The mammary tumor frequency of female C3H mice can be 
reduced by nursing newborn pups on BALB/c foster mothers.  The resulting strain, 
C3HfBALB/c, has a 40% mammary tumor incidence.  Conversely, the reciprocal strain, 
BALB/cfC3H, has a high incidence of breast cancer.  Further experiments have 
established that C3H mice have a virulent milk-borne virus called C3H MMTV or 
MMTV(C3H) as well as a replication-competent endogenous provirus, Mtv1 (57). 
Both endogenous and exogenous MMTVs encode a superantigen (Sag) in their 
LTRs (109).  Sag is important for trafficking of exogenous virus from the gut of 
susceptible pups to the mammary epithelial cells (74).  The LTR sequences of different 
MMTVs are relatively conserved, yet the region encoding the C-terminal region of Sag 
is hypervariable, allowing various MMTV Sag proteins to interact with different subsets 
of T cells (212,219).  Endogenous MMTVs that express Sag in the developing thymus 
eliminate Sag-reactive T cells, which are required for infection by exogenous viruses 
with same Sag specificity (84).   
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Host factors in different strains also influence susceptibility to disease induced 
by MMTV infection.  C3H/HeJ mice have a greatly increased latency for mammary 
tumor induction after infection with milk-borne MMTV (C3H) relative to other substrains 
of C3H mice.  These mice are highly susceptible to bacterial lipopolysaccharide (LPS) 
because they are unable to mount innate immune responses to this molecule.  
Recently, the lps gene was cloned and shown to encode toll-like receptor 4 (TLR4) 
(166).  C3H/HeJ mice carry an attenuated milk-borne MMTV that appears to be the 
result of genetic selection for an altered immune response to the virus (158).  C57BL 
mice also are resistant to MMTV-induced disease.  These mice lack MHC class II I-E 
chains (143), which are necessary for efficient Sag presentation and function during 
MMTV trafficking to the mammary gland.  I/LnJ strain mice represent another inbred 
mouse strain with genetic resistance to MMTV infection.  These animals fail to develop 




MMTV develop hyperplastic alveolar nodules (HANs) or plaques that often 
result in mammary carcinomas (133,216).  There is a long latency between milk-borne 
viral infection from the gut and the development of mammary tumors, suggesting that 
MMTV does not contain an oncogene.   Several investigators have shown that tumors 
arise due to multiple insertions near cellular oncogenes.  Int1 was the first common 
integration site to be identified in MMTV-induced tumors (153). Gene structure and 
nucleotide sequence indicated that Int1 encodes a highly conserved growth factor that 
 
  18  
is involved in wing development in Drosophila (9,204) and, therefore, the hybrid name 
Wnt1 was derived.  Many other common integration sites have now been identifid for 
MMTV-induced mammary tumors, including genes encoding many growth factors of 
the Wnt or Fgf families: Fgf3 (Int2), Notch4 (Int3), Wnt3 (Int4), Cyp19a1 
(Cyp19/Int5/IntH/aromatase), Fgf4 (Hstf1/Fgfk), Fgf8, Eif3s6 (Int6), and Wnt10b (154).   
MMTV also induces T-cell lymphomas.  MMTV proviruses from T-cell 
lymphomas invariably contain 350 to 500 bp deletions in the negative regulatory 
elements (137,213).  Some MMTV proviruses isolated from lymphomas also contain 
duplicated sequences that have been shown to contain T-cell enhancers (137).  
Chimeric MMTVs in which the LTR from a mammotropic MMTV clone was replaced by 
the rearranged LTR from a lymphomagenic MMTV caused lymphomas in BALB/c mice, 
whereas the mammotropic clone induced mammary tumors only (213,214). Additional 
experiments have shown that the ability to induce lymphomas maps to the NRE and 
duplicated sequences in the U3 region. These results indicate that the tissue specificity 
of MMTV-induced disease is determined by the U3 region of the LTR. 
 
1.2 THE NUCLEAR MATRIX  
1.2.1 Identification of the nuclear matrix 
Eukaryotic cell nuclei are mainly composed of DNA and histone complexes.  
However, the elution of these elements by high-salt extraction does not disrupt nuclear 
structure.  The residual structure that retains the shape and some morphological 
features of the nuclei after sequential extraction of nuclei with detergents, nucleases, 
and high salt was originally defined as the nuclear matrix (16).  A similar nuclear 
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remnant extracted with a mild ionic detergent, lithium 3, 5-diiodosalicylate (LIS) was 
labeled the nuclear scaffold (141); however, nuclear cage, nuclear ghost and nucleoid 
core are different names for the similar structures (95).  Nuclear matrices are 
composed of a nuclear lamina with residual nuclear pore complexes, residual nucleoli, 
and an internal network of filaments connecting the residual nucleoli with the lamina 
(18) (Fig. 4).  Therefore, the nuclear matrix consists of a peripheral lamina-pore 
complex and an intricate internal fibrogranular structure.  
 
1.2.2 Nuclear matrix proteins 
Initial analysis of the nuclear matrix showed that lamins are the major 
components of the lamina (15).  Later, DNA topoisomerase II and nuclear mitotic 
apparatus protein (NuMA) were identified as constituents of the nuclear matrix 
(19,128).  Subsequent studies by in vivo labeling with [35S] L-methionine and two-
dimensional electrophoresis showed that the nuclear matrix contains more than 200 
different proteins.  However, the composition of the nuclear matrix varied depending on 
the cell type.  Twelve major proteins from rat liver nuclear matrix were separated and 
purified by peptide mapping and identified by antibody cross-reactivity.  Five of these 
proteins were shown to be lamins A, B, and C, the nucleolar protein B-23, and core 
heterogeneous nuclear ribonucleoproteins (hnRNPs).  The remaining proteins were 
unknown and were defined as the nuclear matrin (150).  Recently, a new database that 
contains 398 nuclear matrix proteins, was construced through analyzing over 3000 
scientific articles in PubMed (139).   
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Fig. 4. Diagram of the nuclear matrix. 
The nuclear matrix is defined as the residual structure following extensive 
extraction of chromatin and most soluble proteins.  The diagram represents the nuclear 
matrix structure.  The nuclear lamina define the outermost positions of the matrix.  
Inside the lamina, internal filament networks and the nucleolus are interconnected by 
lamina.  Ovals indicate the sites that are important for nuclear reactions such as 
transcription, replication, and splicing. 
 
Interestingly, it was shown that malignant cells express a different composition 
of nuclear matrix proteins compared to normal cells, and some researchers have found 
such proteins to be useful as cancer cell markers (27,70,126).  Recently, mass 
spectrometry has been used to identify new matrix proteins (155).  
Networks among the matrix or other regulatory proteins are formed to maintain 
the integrity of the nuclear matrix and to regulate important nuclear reactions.  Nuclear 
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lamins, members of the intermediate filament protein family, are an example of this.  
They are integral components of the nuclear lamina, providing the structural framework 
for the nuclear matrix, as well as functioning as a regulator of transcription and splicing 
(90,116). 
Keratin 19, one of the nuclear matrix intermediate filaments, is expressed in a 
tissue and differentiation-specific manner.  This protein binds to human RNA 
polymerase II subunit 11, implying a relationship between nuclear matrix and 
transcription (28).  One nuclear receptor, GR, which binds to the nuclear matrix, is 
important for the hormonal regulation of many cellular and viral promoters, including 
the MMTV LTR.  The nuclear matrix targeting sequence (NMTS) of GR was 
determined to be a DNA-binding domain linked to the tau2 transactivation domain.  
One of the nuclear matrix proteins, hnRNP U, was shown to be responsible for GR 
binding to the nuclear matrix (199). 
   
1.2.3 Nuclear matrix and loop structure 
Chromatin fibers of chromosomes are organized by attachment to the nuclear 
matrix to form 30- to 100- kbp loop structures (2,103,118,160). The attachment sites 
are called the matrix/scaffold attachment regions (MAR/SARs), which are long 
stretches (200-800 bp) of AT-rich DNA containing consensus recognition sequences 
for topoisomerase II binding (21,22).  MARs have been shown to be favored sites for 
histone H1 binding in vitro and may play a role in H1-dependent chromatin repression 
(102,188).  It has been suggested that MARs also act as facilitators of replication by 
modulating chromatin architecture. The amplified dihydrofolate reductase domain 
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(amplicon) in CHOC 400 cells (140) contains MAR sequences (54).  The replication 
origin regions in the amplicon undergo dramatic alterations in micrococcal nuclease 
hypersensitivity in a cell-cycle dependent manner when copies of the amplicon are 
affixed to the nuclear matrix (162).    
MARs act as important transcriptional regulators by regulating chromatin 
structure (79).  For example, MARs that flank the immunoglobulin heavy-chain 
enhancer are necessary to activate the distal variable-region promoter in transgenic 
mice (44,98).  Mechanistically, it has been suggested that MARs regulate chromatin 
structures because most of the HAT and HDAC activities are associated with the 
nuclear matrix (49).  Furthermore, MARs enhanced the acetylation of histones at the 
immunoglobulin heavy-chain enhancer distal nucleosomes, suggesting that MARs 
function to mediate long-range chromatin accessibility and transcriptional activation 
(63).  Moreover, transcription can be regulated by MAR-binding proteins.  This 
regulation is exemplified by the role of B cell regulator of IgH transcription (Bright) on 
gene expression from the immunoglobulin heavy chain intronic enhancer (101) as well 
as the ability of SATB1 to influence expression of a reporter gene flanked by MAR 
sequences (111). 
 
1.2.4 The role of the nuclear matrix in transcription 
A large body of evidence from different experimental systems suggests that the 
nuclear matrix plays an important role in transcription, perhaps by serving as a 
concentration site for transcription factors.  Solubilized nuclear matrix proteins 
specifically bind to sequences within MARs, suggesting that sequence-specific DNA-
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binding proteins localize in the nuclear matrix (60).  Nuclear matrix proteins from HeLa 
S3 cells and rat ROS 17/2.8 cells have been shown to contain proteins that bind to 
well-characterized consensus sequences of Sp1, ATF, CCAAT, C/EBP, Oct1 and AP-1 
(101).  A developmentally important regulator, Pit-1 activates prolactin, growth 
hormone, and its own gene, pit1, and is localized in the nuclear matrix.  However, 
some point mutations leading to dwarfism change its nuclear localization, suggesting 
that transcription factor activity is associated with nuclear architectures (129).     
Fractionation studies show that transcriptionally active DNA is tightly associated 
with the nuclear matrix, whereas inactive loci are not.  The ovalbumin gene in the 
chicken oviduct is associated with the nuclear matrix when the gene is stimulated by 
steroid hormones.  However, when the hormone is withdrawn, the gene is detached 
from the nuclear matrix (42).  The integrated polyoma and avian sarcoma virus (ASV) 
genomes in transformed cells also are associated with the nuclear matrix, but two 
subclones that lost the transformed phenotype and contained no detectable viral 
transcripts showed little association with the nuclear matrix (46). 
Transcription complexes, including nascent transcripts with active RNA 
polymerases, are known to be associated with nuclear matrix that has been isolated 
under isotonic conditions (94,105).  The finding that actively transcribed genes are 
associated with the nuclear matrix suggests that the nuclear matrix is involved in the 
global organization of chromatin.   
Chromatin is organized into loops of heterogeneous size and the bases of 
these loops bind to the nuclear matrix through MARs/SARs.  When the 5’-MAR of the 
chicken lysozyme-gene was linked to a reporter gene, the reporter expression was 
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significantly elevated regardless of the integration sites in its stable transfected cells 
(194).  When the human interferon-beta (huIFN-β) gene was flanked by SARs, 
transcription increased 20- to 50-fold compared with the gene without SARs.  
Furthermore, transcriptional activation by SARs was orientation- and somewhat 
distance-independent (108). 
Steroid receptors, such as the androgen receptor and the glucocorticoid 
receptor, bind to the nuclear matrix (205).  Highly purified GR has been shown to bind 
to the nuclear matrix in vitro (107), but binding is dependent on the ATP concentration 
in the nucleus.  GR binding to the nuclear matrix is dramatically increased by the 
depletion of ATP.  However, GR is released into the soluble nuclear compartment with 
restoration of normal ATP levels (198).   
 
1.2.5 Nuclear matrix role in replication and splicing 
Several lines of experimental evidence suggest that the nuclear matrix plays 
important roles in DNA replication.  Labeling of newly synthesized DNA with [3H] 
thymidine showed that the nuclear matrix is associated with 90% of the newly 
synthesized DNA found in rat liver (17). Active DNA replication enzymes, including 
DNA polymerase α (190), DNA primase, 3’ to 5’ exonuclease, RNase H, and DNA 
methylase, are associated with nuclear matrix isolated from regenerating rat liver (203).    
Replication origins are not permanently associated with the nuclear matrix (55).  
However, the association is controlled in a cell cycle-dependent manner.  That is, 
replication origins associate with the nuclear matrix in late G1 phase and dissociate 
after initiation of replication in S phase (56). Immunolabeled DNA sites show that each 
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cell has approximately 150 focal sites of synthesis.  The number of foci remains 
constant, even in cells from which 90% of the chromatin has been removed, 
suggesting that DNA replication is occurring on the nuclear matrix (87).  
The splicing machinery is also associated with the nuclear matrix.  Nuclear-
mitotic apparatus protein (NuMA) colocalizes with splicing factors and is associated 
with small nuclear ribonucleoproteins (snRNPs), consistent with the relationship 
between RNA processing and the nuclear matrix (222).  Furthermore, an intron-
containing segment of the rabbit globin gene was transfected into HeLa cells to 
determine whether splicing occurs on the nuclear matrix.  The reporter pre-mRNA, its 
splicing intermediates, and the resulting products associated with the nuclear matrix 
(221).  When the nuclear matrix was incubated with in vitro HeLa splicing extract, the 
amount of matrix-associated precursor decreased, and the corresponding free intron 
lariat increased (221). 
The nuclear matrix is also involved in the transportation of processed RNAs 
between subnuclear compartments.  In fractionation experiments, spliced introns and 
pre-mRNAs of placenta and embryonic expression protein (Pem), a homeobox 
transcription factor, are present in the nuclear matrix fractions as well as in the high 
salt-soluble and chromatin-associated fractions (43).  This result suggests that 
transcription and RNA processing occur in the same nuclear compartments, including 
the nuclear matrix. (43).  Moreover, E1B 55kD protein encoded by adenovirus type 5 
binds to the nuclear matrix in an E4 Orf6 protein-regulated manner and facilitates 
subnuclear RNA transport (120,121).  
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1.3 SPECIAL AT-RICH BINDING PROTEIN 1  
1.3.1 Identification of SATB1 
Repeats of sequences derived from the MAR located 3’ of the mouse 
immunoglobulin µ heavy chain gene enhancer were used to screen a human testis 
cDNA expression library.  From this screen, a new MAR-binding protein of 763 amino 
acids was cloned and identified as special AT-rich sequence binding protein 1 (SATB1) 
(53).  SATB1 is expressed in a tissue-specific manner, primarily in thymus.  
Furthermore, this factor binds to AT-rich MAR sequences, but not to AT-rich non-MAR 
sequences (53).   
Mouse SATB1 cDNA was cloned to determine the conservation of the SATB1 
gene among different species.  The murine protein has 764 amino acid residues with 
98% homology to the human SATB1 sequence (149).  A novel motif, a symmetric  
structure with a loop containing two short stretches of hydrophilic amino acids, was 













Fig. 5. Schematic diagram of SATB1  
Positions of the dimerization domain, the MAR-binding domain, the Cut-like 
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1.3.2 Functional domains 
To understand the mechanism of SATB1 action, functional domains of the 
protein have been identified.  SATB1 contains a dimerization domain at the N-terminus 
followed by two Cut-like repeats, a MAR binding domain near the middle of the protein, 
and a homeodomain at the C-terminus (Fig. 5).  It was originally suggested that SATB1 
binds to DNA as a monomer, but subsequent experiments have shown that SATB1 
functions as a homodimer.  Deletion of the dimerization domain abolishes DNA 
binding, although the truncated protein has an intact MAR-binding domain and a 
homeodomain (68).  The homeodomain per se does not bind DNA, but acts with the 
MAR-binding domain to participate in specificity of association with the core-unwinding 
element within the base-unpairing region (52). 
SATB1 has been reported to recognize a specific sequence context in which 
one strand consists exclusively of mixed A, T and C nucleotides (ATC sequences) (53).  
AT-rich sequences in MARs have a strong tendency to unwind by extensive base 
unpairing (110).  However, one SATB1-binding site in the MMTV LTR has G residues 
(124).  SATB1 binding is highly specific and does not bind to similar AT-rich sequences 
lacking these unwinding capabilities.  Moreover, this factor recognizes the minor 
groove of DNA with little contact with the bases (53). 
  To delineate the MAR-binding motif of SATB1, a random nanomeric peptide 
library constructed in a bacteriophage was incubated with the concatemerized 25-bp 
SATB1 recognition sequence from the IgH MAR. A peptide sequence (RQNWGLEGC) 
was selected as the MAR-binding motif.  This peptide has 50% identity with a SATB1 
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sequence (amino acids 355-363), and replacement of the wild-type sequence with the 
new MAR binding motif in SATB1 gave full MAR-binding activity (207). 
 
1.3.3 Interacting proteins 
To further elucidate SATB1 function, a number of interacting proteins have 
been identified.  A novel variant of RNA polymerase II, subunit 11 (RPB11) was 
obtained from a Jurkat T-cell cDNA library through yeast two-hybrid screening with 
SATB1.  SATB1 interacts with RPB11 through the dimerization domain (PDZ domain) 
(59).  SATB1 binds to CCAAT displacement protein (CDP), which is both a repressor 
and an activator of many cellular genes, depending on the promoters.  Both SATB1 
and CDP act as repressors on the MMTV promoter, but interactions between SATB1 
and CDP abolishes DNA binding, thus relieving the transcriptional suppression (123). 
The X-linked lymphocyte-regulated (Xlr) protein, which is expressed in late stage B-
lymphoid cell lines, also colocalizes with SATB1 in pre-T lymphocytes (62).   These 
results confirm a role for SATB1 in transcription regulation, particularly in the lymphoid 
cell lineage.  
SATB1 also interacts with several proteins involved in chromatin remodeling.  
Co-immunoprecipitation with ISWI, Mi-2, MTA-2 and HDAC1 suggests that SATB1 
assembles protein complexes containing factors found in CHRAC/ACF and NURD 
complexes.  The factors, hSNF2H and hACF1, components of the CHRAC/ACF 
remodeling complex, and HDAC1 directly interact with SATB1. Multimerized BUR 
elements from a MAR 3’ of the immunoglobulin heavy chain enhancer were used in an 
affinity column to purify SATB1 and SATB1 binding proteins in thymus extract.  SATB1 
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was copurified with the NURD (nucleosome remodeling and histone deacetylase) 
complex that has been implicated in transcriptional repression in several genes.  The 
NURD complex contains ATP-dependent remodeling enzyme Mi-2, histone 
deacetylase 1 and 2, histone deacetylase associated co-repressor mSin3A, and MTA-
2.  In addition to the NURD complex, SATB1 binds to nucleosome-dependent ISWI-
ATPase and ACF1, both subunits of the CHRAC/ACF complexes.  Since SATB1 is 
bound to the bases of chromatin loops, these interactions may indicate that SATB1 
targets chromatin remodeling complexes to specific nuclear locations to regulate gene 
expression (218).   
 
1.3.4 SATB1-knockout mice 
SATB1-null mice are smaller and thinner than their littermates and usually die 
within 4 weeks of birth.  These animals exhibit neurological defects, such as 
incomplete eye opening and the clasping reflex.  In addition, they have small thymi, 
spleens and lymph nodes with histologic abnormalities, and the number of thymocytes 
is reduced 10- to 100- fold by 3 weeks.  These characteristics of SATB1-null mice are 
consistent with the fact that SATB1 mRNA is expressed primarily in thymus as well as 
fetal brain.  Of the nearly 600 genes surveyed in SATB1-null thymocytes, 
approximately 2% showed differences in expression. Nine of ten genes tested by RT-
PCR had increased expression, including c-myc, consistent with a primary role for 
SATB1 in transcriptional repression. The dysregulation of multiple genes in SATB1-null 
mice and the strong binding affinity of SATB1 for base-unpairing regions (BURs) leads 
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to the hypothesis that SATB1 functions to provide assembly sites for chromatin 
remodeling to orchestrate gene expression during thymic development.   
The IL-2Rα gene is ectopically transcribed in SATB1-null thymocytes, although 
the SATB1-binding site is located 6.8 to 7.5 kb downstream of the transcriptional start 
site of this gene.  Chromatin immunoprecipitation (ChIP) and micrococcal nuclease 
digestion of the IL-2Rα gene locus showed that SATB1 can regulate nucleosome 
positioning and acetylation of histones as far as 7 kb from its binding sites (218).  
 
1.3.5 SATB1 as a transcription regulator 
 SATB1 has a dense three-dimensional cage-like distribution even after high 
salt extraction and DNase I digestion of thymocytes.  This cage-like SATB1 distribution, 
which is referred to as a SATB1 network, plays an active role in chromatin alterations 
of the myc locus and in myc gene expression in thymocytes.  The chromatin regions in 
thymocytes that bind to the SATB1 network were cloned.  Genes within 50 kb of these 
regions were regulated by tethering to the SATB1 network.  In addition, a region of the 
γ-globin locus associates with the nuclear matrix.  Two sites within the element bind to 
SATB1, implying that this region may affect gene expression by nuclear matrix binding 
(48). However, tethering of genes to the SATB1 network and orchestrated histone 
acetylation and methylation can result in repression, activation, or induction, depending 
on the locus (30).  
The DNase I-hypersensitive site (HS1) in the T-cell receptor (TCR) α locus is 
induced during differentiation of CD4-CD8- to CD4+CD8+ thymocytes.  This HS1 
region, which binds both SATB1 and CDP, associates with the nuclear matrix in vitro.  
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When the HS1 region was linked with a reporter gene along with the enhancer 
sequence Eβ and transiently transfected into four thymoma lines, reporter gene 
expression was suppressed 2.5-fold compared to that of the reporter gene containing 
only Eβ.  This result implies that SATB1 acts as a repressor of TCR transcription (38). 
Various MAR sequences were linked with a reporter gene and stably 
transfected into BHK cells, which contain concatemerized 25-bp repeats [25]7 of the 
core unwinding region, a 2.2 kb MAR fragment from upstream of the human interferon-
beta (hnIFN-β), and a 1.8 kb MAR from upstream of the potato ST-LS1 gene.  
Overexpressed SATB1 dramatically suppressed expression of the reporter genes 
linked to the MAR sequences (111).  Furthermore, SATB1 has at least 7 binding sites 
within the gp91phox promoter.  A strong SATB1-binding sequence and a binding mutant 
were each linked with a reporter gene and transiently transfected into human 
erythroleukemia (HEL) cells.  The reporter gene expression was down-regulated by the 
wild-type, but not the mutant SATB1-binding sequence (80). 
As suggested by experiments with SATB1-null mice, this transcription factor 
also may function as an activator.  SATB1 binding as well as DNase I hypersensitivity 
and nuclear matrix-binding assays were used to identify regulatory regions of the CD8 
gene (104).  SATB1 binds to a MAR element (L2a) in an upstream regulatory region of 
the mouse CD8α gene (10), where it displaces the CDP repressor (10).  The  gamma-
globin promoter and enhancer binding factor (γPE) is a large nuclear complex that 
contains SATB1 and HOXB2 proteins and binds to five sites located 5’ and 3’ of the 
human γ-globin gene.  SATB1 causes an increase in the luciferase reporter activity, 
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whereas HOXB2 decreases reporter gene activity from the reporter gene with the γPE-
binding site (32).  
SATB1 also may have additional functions. The major breakpoint region (MBR) 
in the untranslated portion of terminal exon 3 of BCL2 is a hot spot for the t(14;18) 
chromosomal translocation in lymphomas, resulting in inactivation of the oncogene 
BCL2 and its ability to facilitate apoptosis (132,202).  SATB1 was shown to bind to the 
33-bp core region of the AT-rich MBR sequence by affinity purification.  The MBR is a 
MAR sequence that contains multiple, constitutive, DNase I-hypersensitive sites of a 
SATB1-binding site.  SATB1 binding to the MBR may enhance the intrinsic fragility of 
the matrix attachment region (172). 
 
1.3.6 Role of SATB1 in apoptosis 
SATB1 reportedly is specifically cleaved by caspases during apoptosis, but not 
during necrosis.  The cleavage site of SATB1 has been mapped to the N-terminal 
region just before the MAR-binding domain.  This site contains the VEMD sequence, 
which matches the cleavage motif for caspase-6, VEXD (77).  However, a conflicting 
report showed that cleaved SATB1 fragments of 70 kD, a size similar to that of the 
apoptotic signature fragment, are detected during necrosis (23) and SATB1 in the 
nuclear matrix remains uncleaved in apoptotic HL-60 cells (130).  These contrasting 
conclusions may result from degradation of different sets of nuclear matrix proteins 
during apoptosis, depending on the effectors and/or cell lines.  Alternatively, SATB1 
might be degraded during apoptosis, but the degradation product does not remain in 
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the nuclear matrix after cleavage.  Therefore, the cleaved fragments would not be 
detected in the nuclear matrix of apoptotic HL-60 cells (130). 
The site-specific cleavage of SATB1 during apoptosis initiates DNA degradation 
at the SATB1-binding site.  A number of genes, including the c-myc proto-oncogene 
and high-mobility group phosphoprotein (HMG), were selected for analysis due to their 
high similarity to the 25-bp BUR element of the IgH gene that is known to contain a 
SATB1-binding site.  Subsequently, ligation-mediated PCR (LM-PCR) revealed an 
increased accumulation of single-stranded DNA breaks in close proximity to these 
regions relative to adjacent stretches of DNA (125).   
 
1.3.7 SATB1-binding sequences 
Genomic SATB1-binding sequences in vivo have been isolated by 
immunoprecipitation of Jurkat T-cell lysates with SATB1-specific antibody on 
crosslinked and Sau3AI-digested chromatin.  Cloning and sequencing revealed 16 
SATB1-binding sequences (SBSs), and three were chosen as DNA probes for in situ 
hybridization experiments. These experiments showed that the SBSs remained bound 
to the nuclear matrixes after extensive in situ nuclear matrix preparation using washes 
with 2M NaCl and nuclease digestion.   These results suggested that SATB1 binds to 
the bases of chromatin loops.  In situ hybridizaion with a SBS in a human breast 
cancer cell line (SK-BR-3), which does not express SATB1, gave undetectable signal 
in the nuclear matrix (31,50), suggesting that chromatin anchoring to the nuclear matrix 
and loop formation also is cell-type dependent.  This higher order chromatin 
organization by SATB1 may regulate tissue-specific gene expression. 
 
  34  
Nuclear matrix proteins isolated from breast tumor tissues specifically bound to 
the MAR of the c-erbB-2 promoter region, but these proteins were not found in nuclear 
matrix from normal breast tissues.  The MAR-binding activity of SATB1 was detected 
only in human breast carcinomas, but not in normal breast tissue, suggesting that 
SATB1 plays an important role in breast cancer progression (215). 
 
1.3.8 Role of SATB1 in MMTV transcription 
Deletion analysis of the MMTV LTR localized the negative regulatory elements 
(NREs) to the MMTV U3 region.  Two regions, one between -484 and -424 and the 
other between -281 and -255, were shown to be important for NRE function on basal 
transcription from the MMTV LTR.  Furthermore, two protein complexes, referred to as 
upper binding protein (UBP) and NRE-binding protein (NBP) specifically bound to the 
100-bp fragment in the NRE.  The NBP complex had a cell-type specific distribution 
since it was detectable in extracts from T cells, but not mammary cell (25).  Purification 
and mass spectrometry revealed that a major component of NBP was SATB1.   
SATB1 binding was shown to have a dramatic effect on tissue-specific 
expression from the MMTV LTR.  A mutant-LTR plasmid (p924) with a 7-bp 
substitution mutation the SATB1-binding site of the proximal NRE had a 2.6-fold 
elevation of basal LTR transcription over that of plasmids with the wild-type MMTV 
LTR.  Furthermore, transgenic mice carrying an MMTV LTR with the mutation exhibited 
a dramatic alteration in their expression pattern (124).  Lymphoid tissues, such as the 
spleen, thymus, Peyer’s patches, and lymph nodes of the transgenic mice with the 924 
mutation showed 10 to 100-fold higher expression of the transgene when compared to 
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other organs, including lung, kidney, and mammary gland tissues.  In contrast, mice 
expressing wild-type MMTV LTR-reporter genes showed the highest expression in 
lactating mammary tissues, and lower expression in lung, kidney, and lymphoid 
tissues.  Since SATB1 binds to a MAR within the negative elements, these results are 
consistent with SATB1-mediated repression of MMTV expression in several cell types, 
including T cells. 
 
1.4. RATIONALE FOR THIS STUDY 
MMTV causes mammary adenocarcinomas in susceptible mouse strains.  Milk-
borne or exogenous MMTV infects lymphoid cells that deliver the virus to mammary 
epithelial cells, the final destination of the virus (57).  Despite the fact that lymphoid 
cells are infected, wild-type MMTV does not cause lymphomas.  MMTV variants that 
cause thymic lymphomas contain a 300- to 500-bp deletion in the U3 region of the 
LTR.  The deleted region binds to at least two cellular proteins, CDP and SATB1 (124).  
SATB1 is believed to be the primary regulator of MMTV expression in T cells (53) 
because of its abundant expression in thymocytes and T-cell lines (124,184).  Although 
experiments in transgenic mice and in transient assays with mutant LTRs suggest that 
SATB1 is a repressor of MMTV expression (25,124), a direct relationship between 
SATB1 and MMTV transcription has not been demonstrated.  Furthermore, the 
mechanism by which SATB1 suppresses MMTV expression is not clear. 
In this study, SATB1 domains necessary for transcriptional suppression of the 
MMTV LTR from integrated templates were elucidated.  These experiments should 
lead to a better understanding of tissue-specific MMTV expression. 
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2. MATERIALS AND METHODS 
 
2.1. PLASMIDS  
Wild-type and mutant SATB1 cDNAs were cloned into the pUHD10-3 vector 
and overexpressed in MCF-7 cells stably transfected with the transactivator [MCF-
7/Tet-off (Clontech)] or in cell lines expressing the transactivator plasmid, pUHD15-1.  
The UHD vectors were provided by Dr. Paul Bates (University of Pennsylvania School 
of Medicine).  Full-length mouse SATB1 cDNA from pMAT (provided by Dr. Kohwi-
Shigematsu) was inserted into the EcoRI site of pUHD10-3 to make pUHD10-3/SATB1.  
For the SATB1(1-345) and SATB1(1-494) constructs, full-length SATB1 cDNA was 
digested with ScaI or AseI, respectively, and treated with Klenow enzyme.  Each 
fragment was then inserted into the EcoRI site of pUHD10-3.  Full-length SATB1 cDNA 
was digested with both ScaI and AseI, treated with mung bean nuclease, and ligated.  
This fragment was inserted into the Klenow-treated EcoRI site of pUHD10-3 to make 
ID(346-494).  pUHD10-3/SATB1 was prepared by digestion with EcoNI, treated with 
mung bean nuclease, and sequentially ligated to make ID(274-410).  The pUHD10-
3/SATB1 plasmid was digested with EcoNI and BamHI, treated with Klenow enzyme, 
and self-ligated to construct SATB1(1-274).  The plasmids SATB1(1-224), SATB1(55-
764), SATB1(168-764), and SATB1(275-764) were created by PCR with primer pairs: 
SATB199EGFP and SA870DO, SA631UP and SA2497DO, SA700UP and SA2497DO, 
and SA1021AUG  and SA2497DO, respectively.   The PCR products were digested 
with EcoRI and inserted into the EcoRI site of pUHD10-3. The construct ID(224-278) 
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was prepared by recombinant PCR with 4 primers: SA196+, SA867-, SA1033+ and 
SA2497DO.  Briefly, the recombinant PCR was accomplished using two rounds of PCR 
as previously described (67).  Two fragments were separately amplified using SA196+ 
and SA867- primers or SA1033+ and SA2497DO primers with pMAT as the template.  
After combining the two PCR products, a third round of PCR was performed with 
SA196+ and SA2497DO primers. 
For construction of pEGFPC1-NMTS and pLexA-NMTS, the SATB1 NMTS was 
amplified by PCR with Sagfp865+ and SA1032- or Sagal865+ and SA1032- primers.  
The products were cloned into the EcoR1 site of pEGFPC1 (Clontech) or pLexA 
(generously provided by Dr. Paul Gottlieb at the University of Texas at Austin), 
respectively.  To prepare pGFP-SATB1, pGFP-SATB1(1-55), and pGFP-SATB1(1-
224), fragments were amplified by PCR using primer pairs SATB199EGFP and 
SA2497DO, SATB199EGFP and SA363DO, and SATB199EGFP and SA870DO, 
respectively.  The products were cloned into the EcoR1 site of pEGFPC1 (Clontech).  
The plasmid pGBKT7-NMTS was constructed by PCR amplification of the SATB1 
NMTS with primers Sagal865+ and SA1032 and insertion into the EcoRI site of 
pGBKT7.  
Myc-tagged lamin A (pCI-mycLMNA), lamin C (pCI-mycLMNC), and pCI-LMNB 
vectors were generously provided by Dr. Sue Shackleton (University of Leicester, UK).  
Incorporation of the Myc-tag in pCI-LMNB was accomplished by swapping the lamin B 
fragment obtained by digestion with SalI and EcoRI with fragments obtained using 
MycLamin369+ and Lamin802-. 
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Primers SA196+ and SA2497DO and SA196+ and SA1686-, respectively, and 
pMAT were used as template for PCR, and the products were inserted into the EcoRI 
site of MigR1 to produce retroviral expression vectors MigR1-SATB1 and MigR1-
SATB1(1-494).  ID(346-494), ID(224-278) [also called ∆NMTS] and SATB1(168-764) 
fragments were digested from ID(346-494), ID(224-278), and SATB1(168-764), 
respectively, and cloned into the EcoRI site of MigR1, resulting in constructs now 
referred to as MigR1-ID(346-494) (also called MigR1-∆DBD), MigR1-ID(224-278) (also 
called MigR1-∆NMTS) and MigR1-SATB1(168-764), respectively.  
For high fidelity, Pfu Turbo DNA polymerase (Stratagene) was used for all 
PCRs as recommended by the manufacturer, except in the 2nd round of recombinant 
PCR for ID(224-278), where Platinum PfX DNA polymerase (Invitrogen) was used.  
The final clones were verified by sequencing or extensive restriction enzyme 
digestions. 
pMTV-LUC/Hyg (pMTV/Luc was previously called pLC-LUC) was made by 
inserting the XhoI fragment from pUHD15-1/hygro(-) into the AatII site of pLC-LUC 
using an XhoI linker.   
 
Table 1. Primers for SATB1 mutant cloning 
Name Sequence 
Lamin802- 5’-TTC GAA TTC AGT GCT GCT TCA-3’ 
MycLamin369+ 5’-AAC CTC GAG AAT ATG GAG CAG AAA CTC ATC TCT GAA 
GAG GAT CTG ATG GCG ACT GCG ACC CCC GTG-3’ 
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SA1021AUG 5’-GCG AAT TCC TGA GTA TGC CAG GAA ACA CAG CTG AG-3’ 
SA1032- 5’-CTG AAT TCT GTG TTT CCT GGG ACA GG-3’ 
SA1033+ 5’-AAC AGC ACG GCT GAG CAG CCT CCA TCC-3’ 
SA1043DO 5’-CGG AAT TCG GCT GCT CAG CTG TGT TTC C-3’ 
SA1686- 5’-GCG AAT TCC TAG GCA TTA ATG TTC ATA GTA TTG-3’ 
SA196+ 5’-CGG AAT TCA GTA TGG ATC ATT TGA ACG AG-3’ 
SA2497DO 5’-CGG AAT TCT CTC TCA GTC TTT CAA GTC G-3’ 
SA363DO 5’-GGC GAA TTC TTA CAC TCC CTG CAT CTT TCC-3’ 
SA631UP 5’-GCG AAT TCC TGA GTA TGG TGC CTT TAA AAC ACT CG-3’ 
SA700UP 5’-GCG AAT TCC TGA GTA TGA TTC AGT TAC ACA GTT GC-3’ 
SA867- 5’-CTG CTC AGC CGT GCT GTT CAC AAT GGA G-3’ 
SA870DO 5’-GGC GAA TTC TTA GTA CGT GCT GTT CAC AAT G-3’ 
Sagal865+ 5’-CGG AAT TCA CGT ACT ATG CAA ATG TC-3’ 
Sagfp865+ 5’-CGG AAT TCT ACG TAC TAT GCA AAT GTC-3’ 
SATB199EGFP 5’-CGG AAT TCA CTG AGT ATG GAT CAT TTG AAC-3’ 
SATB199UP 5’-CGG AAT TCT TAT GGA TCA TTT GAA CGA GGC-3’ 
 
 
2.2. PLASMID DNA PREPARATION 
Luria-Bertani (LB) medium containing specific antibiotics was inoculated with 
cells from a single colony and incubated for 6 to 8 hr.  This culture was then added to 
500 ml of fresh LB medium and incubated overnight.  Alternatively, the plasmid DNA 
was amplified using 170 µg/ml chloramphenicol.  The bacteria were pelleted by 
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centrifugation at 7,000 rpm for 10 min at 4oC.  The cell pellet was suspended in 
Solution I (25 mM Tris-HCl, pH 8.0, 50 mM glucose, and 10 mM EDTA) supplemented 
with 10 mg lysozyme, and then lysed in Solution II (0.2 N NaOH and 1% SDS).  The 
chromosomal DNA, high-molecular-weight RNA, and potassium/SDS/protein-
membrane complexes were precipitated with Solution III (3 M potassium acetate, pH 
5.5).  The plasmid DNA was pelleted with isopropanol and washed with 70% ethanol.  
After dissolving the plasmid pellet in 3.5 ml TE 10:10 (10 mM Tris-HCl, pH 7.4 and 10 
mM EDTA), 4.6 g CsCl and 0.68 ml ethidium bromide (5 mg/ml) were added to the 
solution.  Ethidium bromide and the protein complex were removed, and the 
supernatant was subjected to ultracentrifugation at 50,000 rpm (227,000 Xg) at 20 oC 
for 16 hr.  Ethidium bromide was extracted from purified plasmid DNA using n-butanol 
saturated with G-50 buffer (10 mM Tris-HCl, pH 7.4, 0.1 M NaCl, 2 mM EDTA).  The 
plasmid was reprecipitated with ethanol, washed with 70% ethanol, and resuspended 
in TE 10:10.  Plasmid DNA was treated with 100 µg/ml RNase A, 200U RNase T1, and 
100 µg/ml proteinase K to remove contaminating RNA and proteins.  The solution was 
dialyzed against TE 10:1 (10 mM Tris-HCl, pH 7.4 and 1 mM EDTA).  The DNA was 
precipitated and dissolved in TE 10:0.1 (10 mM Tris-HCl, pH 7.4 and 0.1 mM EDTA). 
 
2.3. CELL CULTURE  
Human 293T kidney cells, BW5147 mouse T cells, and MCF-7/Tet-off human 
breast cancer cells (hereafter called MCF-7) (Clontech) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 
Units penicillin and 100 µg/ml streptomycin (Gibco), 2 mM L-glutamine (Gibco), and 50 
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µg/ml gentamicin.  The media for MCF-7 cells was supplemented with 100 µg/ml 
Geneticin (Gibco) to maintain the transactivator plasmid as recommended by the 
manufacturer.  XC rat fibroblast cells were grown in the same media as that described 
for 293T and MCF-7 cells, except that 5% FCS was used.  C3H/XC cells were made by 
Dr. Jaquelin Dudley by infecting XC cells with the C3H strain of MMTV.  Jurkat human 
T cells were grown in Roswell Park Memorial Institute (RPMI) medium supplemented 
with the same additives as 293T cells.  HC11 cells were grown in RPMI supplemented 
with 10% FCS, 2 mM L-glutamine, 50 µg/ml gentamicin, 10 µg/ml insulin, and 10 µg/ml 
epidermal growth factor (EGF) (Invitrogen).  HC11/MTV-LUC cells and XC/MTV-LUC 
cells kindly were provided by Dr. Keqin Gregg and Dr. Quan Zhu, respectively.  Stably 
transfected XC/MTV-LUC, Jurkat/MTV-LUC, BW5147/MTV-LUC and HC11/MTV-LUC 
cells were grown in the same medium as the parental cells with the addition of 250 
µg/ml hygromycin B (Invitrogen).  All the cell lines were maintained at 37°C in an 
atmosphere of 7.5% CO2. 
To suppress SATB1 expression in MCF-7/Tet-off cells during the selection, 1 
µg/ml doxycycline (DOX) was used for supplementation of the growth medium.  The 
media was changed every 3 days.  SATB1 expression in the stably transfected MCF-
7/SATB1 cells was achieved by using medium without DOX. Dexamethasone (DEX) 
(10-6M) was used in growth medium to induce MMTV expression 24 hr prior to 
extraction of RNA or protein from XC/MMTV, XC/MTV-LUC, HC11/MTV-LUC, and 
BW5147/MTV-LUC cells.  
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2.4. TRANSFECTIONS 
For subcellular fractionation and nuclear extracts, XC and MCF-7 cells were 
plated at densities of 7.5 X 105 and 4 X 106 cells per 60-mm-diameter plate, 
respectively, for 24 hr prior to the transfection procedure.  DMRIE-C reagent 
(Invitrogen) or SuperFect (Qiagen) was used as recommended by the manufacturer to 
introduce the SATB1 (6 µg) and pUHD15-1/hygro (4 µg) constructs into XC cells.  For 
MCF-7 cells, DMRIE-C was used with 6µg of SATB1 construct.  A total of less than 5 
µg of DNA was used with SuperFect as a transfection reagent. 
For reporter gene assays, MCF-7 cells were transfected with 40 µg DNA and 
1X107 cells in 200 µl complete media in a 2mm cuvette (BTX) using a BTX 
electroporator at settings of 150V, R4, and 1750 µF.  The transfected cells were 
incubated for 24 to 48 hr prior to preparation of extracts.   
To prepare BW5147/MTV-LUC, BW5147 cells were electroporated with 40 µg 
pMTV-LUC/Hyg and 1.5 X 107 cells in 300 µl complete media in a 4mm cuvette (Bio-
Rad) using a Bio-Rad electroporator at settings of: high range (700), high capacitance 
(500 V max), voltage 0.3, and capacitance 0.950.  The transfected cells were selected 
with 500 µg/ml hygromycin B (Invitrogen) for 3 weeks. 
Jurkat/MTV-LUC cells were prepared by electroporation of Jurkat cells with 40 
µg pMTV-LUC/Hyg and 6 X 106 cells in 400  µl complete media in a 4mm cuvette (BTX) 
using an Electro cell manipulator (BTX) at settings of 1050 µF, R10, and 260V.  The 
transfected cells were selected with 250 µg/ml hygromycin B (Invitrogen) for 3 weeks. 
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2.5. SUBCELLULAR FRACTIONATION   
Subcellular fractions were prepared according to the method developed by de 
Belle et al. (50) with slight modifications.  MCF-7 cells (4 X 106) were transfected with 
various pUHD10-3/SATB1 constructs and incubated for 24 to 48 hr.  The cells were 
incubated for 4 min in 100 µl of 0.5% Triton X-100 in CSK buffer (10 mM PIPES, pH 
6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, and 1mM EGTA) supplemented 
with 1 mM PMSF, and 1X protein inhibitor cocktail (AEBSF, bestatin, E-64, Leupeptin, 
Pepstatin A, and 1,10-phenanthroline) (Sigma) on ice.  Following centrifugation (6,000 
Xg), the supernatant was removed, and designated as the soluble fraction.  The 
insoluble fraction was suspended in 50 µl CSK buffer and treated with 20 units of 
DNase I (Roche) for 15 min at 37°C, followed by ammonium sulfate precipitation at a 
final concentration of 0.25 M.  The insoluble material was removed by centrifugation at 
6,000 Xg, and the soluble material was designated as the chromatin fraction.  The 
insoluble material was washed with 2 M NaCl in CSK buffer, dissolved in 8 M urea 
buffer (8 M urea in 10 mM Tris-HCl, pH 8.0), and designated the nuclear matrix 
fraction.  The same ratio of each fraction was used for analysis on 8 to 15% SDS-
containing polyacrylamide gels, depending on the size of the SATB1 mutant. 
 
2.6. YEAST TWO-HYBRID SCREEN 
Yeast two-hybrid screening was performed according to the supplier (Clontech).  
Briefly, the SATB1 NMTS was used as bait to screen a human thymus Matchmaker 
cDNA library (Clontech).  The bait and the amplified library were sequentially 
transformed into the yeast strain AH109 using the lithium acetate method.  The 
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transformants were assayed for their expression of histidine (HIS3) reporter gene on 
plates containing selective dropout (SD) media without histidine, tryptophan, or leucine.  
Colonies that grew on the selective medium were replated on the same selective 
medium plates twice to eliminate false-positive clones.  To enrich for the weakly 
interacting clones, the screening was performed in two steps.  First, all of the 
transformants were plated on SD plates lacking tryptophan and leucine to select 
transformants with both pGBKT7-NMTS and pACT2-Library plasmids.  The selected 
transformants then were scraped from the plates, and individual colonies were plated 
on SD medium lacking histidine, tryptophan, and leucine and on SD medium lacking 
histidine, adenine, tryptophan and leucine to select clones interacting with the SATB1 
NMTS.  Positive clones were sequenced, and the interaction was further verified by 
other biochemical methods. 
 
2.7. IMMUNOPRECIPITATION 
The 293T cells in 100-mm plates were transfected with expression vectors as 
described above.  After 24 to 48 hr, cells were collected by centrifugation and washed 
once with PBS.  Protein extracts were obtained by incubation of cell pellets for 5 min 
on a rotating wheel with 600 ul of lysis buffer (50 mM HEPES, pH 7.9, 150 mM NaCl, 
1% Trition X-100, and 10% glycerol supplemented with 1 mM PMSF and protease 
inhibitor cocktail (Sigma; P-9599).  The cell debris was then removed by centrifugation 
(15,000 Xg), and the remaining supernatant was pre-cleared with protein A/G plus 
agarose (Santa Cruz Biotechnology) at 4oC followed by centrifugation at 10,000 Xg for 
20 sec.  The supernatant was incubated at 4oC for 2 hr with Myc-specific (Babco; 1:100 
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dilution), GFP-specific (BD Biosciences; 1:100 dilution), or p300-specific (Santa Cruz 
Biotechnology; 1:50 dilution) antibodies.  Protein A/G plus agarose beads were added, 
incubated for an additional hour, and washed three times with lysis buffer. Samples 
were solubilized in 2X SDS-loading buffer (1X = 0.06 M Tris-HCl, pH 6.8, 1.7% SDS, 
6% glycerol, 0.1 M DTT, 0.002% bromophenol blue), boiled, and separated on 8 to 
10% polyacrylamide gels containing SDS.  
 
2.8. WESTERN BLOTTING AND ANTIBODIES 
Protein samples were mixed with 6X SDS-loading buffer, boiled, and separated 
on 8 to 15% polyacrylamide denaturing gels.  The proteins were transferred to 
nitrocellulose membranes (Schleicher & Schuell) at a constant current of 150 mA 
overnight at 4 oC with transfer buffer (47.8 mM Tris-HCl, pH 8.3, 0.39 M glycine, 0.1% 
SDS and 20% methanol).  The membrane was blocked with TBST buffer (20 mM Tris-
HCl, pH 7.6, 137 mM NaCl, and 0.1% Tween 20) containing 5% milk and incubated 
with primary antibodies in 1% milk in TBST buffer.  The membrane was washed three 
times with TBST buffer and detected by horseradish peroxidase-conjugated antibodies 
that were specific for the primary antibody.  Enhanced chemiluminescence reagents 
(NEN) were used for detection.  The following antibodies were used: mouse 
monoclonal SATB1 (BD Biosciences; 1:2,000 dilution), goat polyclonal GFP (Clontech; 
1:1,000 dilution), mouse monoclonal LexA (Clontech; 1:1,000 dilution), mouse 
monoclonal Myc (Babco; 1:1,000 dilution ).  All secondary antibodies (mouse, rabbit, 
goat immunoglobulin (Ig)-specific antibodies) conjugated to horseradish peroxidase 
were purchased from Jackson Immunoresearch.  p300-specific antibody (Santa Cruz; 
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1:200 dilution), Lamin B-specific antibody (Santa Cruz; 1:200 dilution), and mouse, 
goat, and rabbit normal sera (Santa Cruz; immunoprecipitation controls) were also 
used.  MMTV CA (p27)-specific mouse monoclonal antibodies (dilution 1:50) were 
generously provided by Dr. Tatyana V. Golovkina (The Jackson Laboratory) (167).  
Rabbit polyclonal SATB1- and CDP-specific antibodies have been previously described 
(124).  Rabbit polyclonal SATB1-specific antibodies also were provided by Dr. Paul 
Gottlieb (The University of Texas at Austin) (dilution 1:1,000).  All antibodies were 
diluted in PBS. 
For quantitation, Western blots were incubated with GFP-specific or lamin B-
specific antibodies, washed, and incubated with Alexa Fluor 680-conjugated rabbit Ig-
specific (Molecular Probes) or IRDye800-conjugated goat Ig-specific (Rockland) 
antibodies.  Band intensities were determined using infrared fluorescence and an 
Odyssey imaging system (LI-COR Biotechnology).  Blocking buffer (LI-COR) was used 
for pretreatment of blots and antibody dilution. 
 
2.9. VIRUS PRODUCTION, CONCENTRATION, AND TITERING  
The day prior to transfection, 293T cells (8 X 106) were plated on a 100-mm 
dish.  Cloned MigR1 plasmid, pHIT60 and pHITG were co-transfected at a 2:1:1 ratio 
(total DNA was 8 µg) using SuperFect (Qiagen) according to the manufacturer’s 
directions.  The transfection complexes were incubated for 18 to 20 hr, and then fresh 
medium supplemented with 10 mM n-butyric acid (3 ml) was added to induce virus 
production for 7 hr.  After 24 hr of incubation, the supernatant containing virus particles 
was recovered.  Cell debris was removed by centrifugation at 1,500 rpm (450 Xg).  
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Virus particles remaining in the supernatant were pelleted by ultracentrifugation for 100 
min in a SW55Ti rotor (Beckman) at 20,000 rpm (38,000 Xg).  The viral pellet was 
resuspended in complete media, aliquoted and frozen at -70 oC until needed.  To 
determine the titer, 5 and 10 µl of viral stock were incubated with 1 X 105 Jurkat cells to 
obtain the linear range of infection.  The infection efficiency was determined by 
fluorescence-activated cell sorter (FACS) analysis at 24 to 48 hr post-infection using 
the fluorescence from the expressed gfp gene in the MigRI vector (see below). 
 
2.10. TOTAL RNA EXTRACTIONS AND RNase PROTECTION ASSAYS (RPAs)  
Total RNA was extracted using the guanidinium thiocyanate method with slight 
modifications (41).  Briefly, 1 ml of Solution D (4 M guanidinium thiocyanate, 25 mM 
sodium citrate, 0.5% Sarcosyl, and 0.1 M 2-mercaptoethanol), 0.1 ml 2M sodium 
acetate, pH 4.0, and 1 ml water-saturated phenol were directly added to cells on a 100-
mm dish.  The phenol-treated cell mixtures were transferred into microcentrifuge tubes 
and incubated with 0.2 ml of chloroform for 15 min on ice.  After centrifugation, the 
aqueous phase was mixed with the same volume of isopropanol to precipitate RNA.  
The RNA pellet was washed with 70% ethanol and dissolved in water. 
RNase protection assays were performed essentially as described by Wrona et. 
al. (212) except that hybridizations were performed at 55oC.  C3H riboprobe template 
(pTSau3A) was constructed by inserting the C3H LTR sequence from +843 to +1086 
into the pGEMT-Easy vector (Fisher Scientific).  The pTSau3A plasmid was digested 
with NdeI, and labeled RNA probe was produced using T7 polymerase.  Mouse 
GAPDH and cyclophilin plasmids (Ambion) were used for RNA internal controls as 
 
  48  
recommended by the manufacturer.  Briefly, C3H and internal control probes were 
labeled with α-32P-UTP by in vitro transcription.  The labeled probes were hybridized 
with total RNA by overnight incubation at 55oC in hybridization buffer (80% deionized 
formamide, 400 mM NaCl, 40 mM PIPES, pH 6.4, and 1mM EDTA).  The unhybridized 
RNAs were digested with RNase A and RNase T1 in RNase digestion buffer (300 mM 
NaCl, 10 mM Tris-HCl, pH 7.5, 5 mM EDTA) at 37 oC for 3 hr followed by digestion with 
130 µg/ml proteinase K for 1 hr at 37 oC.  The RNA was precipitated with ethanol, 
resuspended, and fractionated on a 6% sequencing gel containing 7M urea.  The gel 
was dried and subjected to autoradiography.  To quantitate the amount of both C3H 
MMTV and the internal control RNAs, the dried gel was exposed on a phosphoimager 
screen (Molecular Dynamics), and the image analysis was performed using 
ImageQuant software.   
 
2.11. REVERSE TRANSCRIPTASE (RT)- PCR 
Total RNA (20 µg) was treated with DNase I (3U, Invitrogen) for 1 hr at 37 oC to 
digest contaminating DNA.  To stop the reaction, EDTA was added to 0.5 mM, and the 
mixture was heated for 10 min at 70oC.  The DNase-treated RNA was adjusted to 0.58 
mM deoxynucleodtides and 50 pmol oligo(dT)17 (IDT) and boiled for 5 min.  Murine 
leukemia virus RT (500 U, Invitrogen) was added and incubated for 1 hr at 37oC.  The 
cDNA was then used with appropriate primer sets for PCR analysis. 
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2.12. IN SITU NUCLEAR MATRIX INTERMEDIATE FILAMENT (NMIF) 
PREPARATION  
Cells grown on cover glasses were extracted stepwise to prepare nuclear 
matrix intermediate filament (NMIF) according to the method of Javed et. al. (97) with 
slight modifications.  Briefly, cells were extracted twice for 15 min with ice-cold CSK 
buffer.  The chromatin was then digested by two consecutive 30 min incubations at 
25°C with 50 U RNase-free DNase I (Roche Molecular Biochemicals) in DB buffer 
(CSK buffer with 50 mM NaCl).  The NMIF was obtained by further extraction for 10 
min on ice with stop solution (DB with 0.25 M ammonium sulfate).   
 
2.13. INDIRECT IMMUNOFLUORESCENCE MICROSCOPY  
Cells grown on cover glasses were washed with PBS and fixed by treatment 
with 4% ice-cold paraformaldehyde in PBS for 15 min at room temperature.  The cells 
were washed with PBS three times and permeabilized with 0.1% Triton X-100 in PBS 
for 10 min.  Again, the cells were washed with PBS three times.  A primary antibody 
was diluted in antibody dilution solution (ADS:10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
2% FBS, and 0.1% Tween-20) and incubated with the cells on the coverslip for 30 min 
at 37°C.  If the cells were stained with more than one primary antibody, the second 
primary antibody was added after PBS washing and incubated for another 30 min at 
37°C.  Following the final PBS wash, appropriate FITC- or rhodamine- conjugated 
secondary antibodies (Santa Cruz) were incubated with cells for 30 min at 37°C.  The 
stained cells were washed with PBS 3 times and mounted on slides with Vectashield 
(Vector Laboratories) containing 300 nM DAPI to visualize the nucleus.  The images 
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were observed with confocal (Leica TCS 4D) or fluorescence microscopes (Zeiss 
Axioskop).  
 
2.14. REPORTER GENE ASSAYS  
Cells transfected with pMTV-LUC plasmid were collected by centrifugation and 
washed with PBS.  Cell pellets were resuspended in 1X passive lysis buffer (Promega) 
and lysed by two freeze/thaw cycles using a dry ice-ethanol bath and a 37°C 
waterbath.  The protein concentrations were determined using the Bio-Rad Protein 
Assay (Bio-Rad), and similar amounts of protein were used to determine the luciferase 
activity.  Luciferase assays were performed according to the manufacturer’s 
recommendation (Promega; E1980).  The final luciferase activity was normalized to a 
constant amount of protein for each cell lysate.  A Turner TD-20e luminometer was 
used to measure luciferase activity. 
 
2.15. KNOCK-DOWN OF GENE EXPRESSION USING SMALL INTERFERING (si) 
RNAs  
SATB1-specific small interfering RNAs (siRNAs) (Dharmacon, SMART pool 
siRNA) or a non-targeting siRNA (Dharmacon, siCONTROL Non-Targeting siRNA #1) 
were introduced by electroporation.  Briefly, the day prior to transfection, Jurkat/MTV-
LUC cells were diluted two-fold.  Cells (6 X 106) in 400 µl were mixed with the siRNA 
(final concentration of 600 nM) in a 4-mm cuvette (BTX), incubated for 10 min at 25°C, 
and electroporated using the following parameters (1050 µF, R10, and 260V) with an 
Electro cell manipulator (BTX).  For mock transfections, all procedures were performed 
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without siRNA.  The cells were collected between 2 to 3 days after transfection, and 
extracts were prepared for Western blot analysis and luciferase assays.  
 
2.16. NUCLEAR EXTRACT PREPARATION  
A nuclear extraction method (8) was performed on ice or at 4oC in a cold room.  
Approximately 8 X 108 cells (40 confluent 100-mm plates) were washed with PBS, 
centrifuged, and resuspended in ice-cold buffer A (10 mM HEPES, pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM DTT and 0.5 mM PMSF).  The cells were lysed with a 
Dounce homogenizer using a type B-pestle, and the nuclei were collected by 
centrifugation at 800 Xg for 10 min.  The pellet was suspended in buffer A and 
subjected to centrifugation at 25,000 Xg for 20 min.  The nuclear pellet was 
resuspended in buffer C (20 mM HEPES, pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT) and lysed with a Dounce 
homogenizer and a type B-pestle.  The nuclear proteins were further extracted by 
stirring the lysates.  The insoluble fraction was removed by centrifugation at 25,000 Xg 
for 30 min.  The final nuclear extract was dialyzed against 50 volumes of buffer D (20 
mM HEPES, pH 7.9, 20% glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 
mM PMSF) for 4 to 5 hr.  Precipitates from the dialysis were removed by centrifugation 
at 25,000 Xg for 30 min.  The final nuclear extracts were stored at -70oC until needed.  
However, nuclear extracts from transfected cells were prepared more rapidly using NE-
PER nuclear and cytoplasmic extraction reagents (Pierce) according to the 
manufacturer’s recommendations.   
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2.17. ELECTROPHORETIC MOBILITY SHIFT ASSAYS (EMSAs) 
Gel mobility shift assays were performed essentially as described by Dickinson 
et al. (53) and Liu et al.  (124).  Binding reactions were performed in EMSA buffer (10 
mM HEPES, pH 7.9, 50 mM KCl, 2.5 mM MgCl2, 10% glycerol, 1 mM DTT, and 1 mM 
PMSF) containing 0.1 mg/ml poly(dIdC) and nuclear extracts (0.5 µg) in a total volume 
of 10 or 15 µl.  Samples were pre-incubated for 10 min on ice before 32P-labeled 
probes (ca. 2.5 fmol) were added for another 20 min.  The binding mixture was added 
to loading buffer (1X EMSA buffer, 80% glycerol, 0.1% xylene cyanole FF, and 0.1% 
bromophenol blue) and subjected to electrophoresis at 200V for 4 hr using 3.4% or 4% 
polyacrylamide gels. The NRE4 probe containing 4 repeats of a 25-bp strong SATB1 
binding sites in the MMTV promoter-proximal NRE (124) was used for the assays.  The 
gels were dried onto chromatography paper and exposed to X-ray film. 
For antibody ablation assays, sera (1:5 dilution in PBS) were added to the 
binding mixture before adding the labeled probe.  The antibody mixture then was 
incubated for 30 min on ice.   
 
2.18. FLOW CYTOMETRY 
Cells were infected with MigR1-based virus using indicated MOI (see figure 
legends) and expanded for 4 to 5 days.  Since the MigR1 retroviral vector expresses 
GFP from the same mRNA as the cloned gene, the percentage of cells expressing 
GFP was determined by FACS and used to derive the percentage of cells expressing 
the cloned gene in the total population.  Uninfected cells were used as the GFP-
negative control.  The basal level fluorescence from uninfected cells was then set as 
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the threshold defining GFP-positive cells.  The fluorescence of infected cells was 
measured by the BD FACSCalibur Flow Cytometry System.  Data was analyzed using 
CellQuest software (BD Biosciences).  
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3. RESULTS 
 
3.1 DEVELOPMENT OF AN MMTV REPORTER SYSTEM FOR SATB1 FUNCTION 
 SATB1 is a repressor or an activator depending on the promoter context of its 
binding sites (5,32,66,111) .  However, mutational analysis of the MMTV LTR in cell 
culture assays and in transgenic mice indicate that SATB1 negatively regulates MMTV 
expression (25,124).  Deletion of SATB1-binding sites or mutation of a strong SATB1-
binding site at +924 in the MMTV LTR increased reporter gene activity compared with 
that from the wild-type promoter in transient transfection assays (25).  Transgenic mice 
with the +924 substitution mutation had dramatically increased reporter gene 
expression in the thymus relative to the mammary gland compared to that observed for 
animals with the wild-type MMTV LTR transgene (124).  Thymocytes have high levels 
of SATB1 and low levels of MMTV expression, consistent with a role for SATB1 in 
repression of MMTV transcription (53,124).  Nevertheless, a tissue culture system for 
analysis of SATB1 structure/function has not been established.  Therefore, several 
assays were designed based on transfection and transduction of expression plasmids 
into cells with low endogenous SATB1 expression. 
 
3.1.1 Transiently transfected MMTV reporter genes show non-specific 
suppression by SATB1. 
 To develop a tissue culture assay for SATB1 function, it would be useful to 
overexpress wild-type or mutant SATB1 in cell lines that lack endogenous SATB1 
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expression.  Initially, various cell lines were analyzed by Western blot analysis to 
determine the endogenous levels of SATB1.   A mouse mammary cell line (HC11), a 
rat fibroblast cell line (XC), a mouse B-cell line (A20), a mouse T-cell line (BW5147), 
and human breast cancer cell line (MCF-7) showed low SATB1 expression.  A mink 
lung cell line (CCL-64) showed intermediate levels of SATB1, while a human T-cell line 
(Jurkat) showed the highest SATB1 expression among all the cell lines analyzed (Fig. 





















Fig. 6. Levels of SATB1 expression in various cell lines.   
The level of endogenous SATB1 was measured by Western blot analysis and 
incubation with SATB1-specific monoclonal antibody (upper panel).  Actin-specific 
antibody was used to ensure equal protein loading in each lane. 
 
 
 Several reports have indicated that SATB1 is cytotoxic in certain cell types 
(68,111).  Therefore, an inducible gene expression system (Tet-off) was utilized to 
generate cell lines that stably express exogenous SATB1.  The MCF-7/Tet-off 
(Clontech) that stably express a tetracycline-suppressible transactivator were 
transfected by electroporation with a pUHD10-3/SATB1 plasmid carrying a 
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hygromycin-resistance cassette.  Following transfection, hygromycin and a tetracycline 
derivative, doxycycline (DOX), were added to the growth medium to select clones with 
integrated SATB1 transgenes and to suppress SATB1 expression during selection, 
respectively.  Hygromycin-resistant clones were isolated, amplified, and tested for 
SATB1 expression by Western blot analysis.  The lysate from Jurkat cells was used as 
a positive control.  Nine clones showed detectable levels of SATB1 expression, but the 











Fig. 7. Selection of MCF-7/Tet-off cells with inducible high levels of SATB1.  
 MCF-7/Tet-off cells were transfected with pUHD10-3/SATB1.  Following 
transfection, DOX was added to the growth medium to suppress SATB1 expression 
during selection.  Single colonies were isolated and expanded.  Protein extracts from 
each clone (given by numbers above the lane) grown in the absence of DOX were 
prepared and used for Western blot analysis with SATB1-specific antibody (upper 
panel).  Actin-specific antibody was used to verify equal protein loading (lower panel).  
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 Clones 4, 5, 6, 8, and 10 were selected and further analyzed for inducibility and 
effects of SATB1 expression on the MMTV LTR promoter.  All the clones showed 
SATB1 expression in the absence of DOX.  Clones 8 and 10 showed SATB1 
expression in the presence of DOX.  However, the overall SATB1 level was greatly 


























Clone 6 Clone 8
 
Fig. 8.  SATB1 is induced in the absence of DOX in MCF-7/SATB1 clones. 
 Each clone was grown in the presence or absence of DOX for 48 hr.  Protein 
extracts were prepared and analyzed by Western blotting with SATB1-specific 
monoclonal antibody.  Arrowheads indicate the position of full-length SATB1. 
 
 
 To determine whether the exogenous SATB1 in MCF-7/SATB1 cells is capable 
of binding to the MMTV promoter, an electrophoretic mobility shift assay (EMSA) was 
performed using a probe derived from the promoter-proximal MMTV NRE.  The probe 
 
  58  
bound poorly to proteins in nuclear extracts from clones 4, 5, and 10 (data not shown).  
Therefore, a concatemer of a strong SATB1-binding site (NRE4) (124) was used as a 
probe to detect SATB1 binding to the MMTV NRE (Fig. 9).  Binding was detected using 
nuclear extracts from SATB1 stably transfected cells (clone #4), but not with nuclear 
extracts from stable cells carrying the empty vector or in HC11 cells lacking 
endogenous SATB1.  The band had a mobility similar to that detected using extracts 
from Jurkat cells, which express high levels of SATB1.  Furthermore, the binding 
observed using extracts from MCF-7/SATB1 cells was abolished by SATB1-specific 
antibody, but not with CDP-specific antibody. 
 Unfortunately, DOX suppressed expression of a transiently transfected C3H 
MMTV LTR-luciferase (pMTV-LUC) reporter gene in MCF-7/Tet-off cells (Fig. 10).  This 
effect is probably due to the overexpression of the transactivator in MCF-7/Tet-off cells 
since DOX did not affect MMTV transcription in untransfected XC cells (data not 
shown).  Therefore, the effects of SATB1 were determined by comparison of reporter 
gene activities of cells stably transfected with empty vector or with SATB1 in the 
absence of DOX (Fig. 11). 
 To measure effects of SATB1 overexpression on MMTV transcription, MCF-
7/SATB1 and MCF-7/Vector cells were transiently transfected with MMTV-LUC and 
assayed for luciferase activity.  SATB1 overexpression was confirmed by Western blot 
analysis and SATB1-specific antibody.  All clones except clone #10 showed 
suppression of luciferase activity by SATB1 overexpression (Fig. 11).  Clone #10 cells 
had leaky SATB1 expression in the presence of DOX (Fig. 8) and, therefore, cells were 
exposed to the cytotoxic effects of SATB1 during the drug selection period.  Surviving 
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cells might then be resistant to the functional effects of SATB1 overexpression.  It 
should be noted that the clone showing the highest levels of DOX-suppressible SATB1 















































Fig. 9. SATB1 overexpressed in MCF-7/SAB1 cells binds to the NRE4 probe. 
 Nuclear extracts were prepared from stably SATB1-transfected clone #4 (MCF-
7/SATB1) and cells stably transfected with the empty vector (MCF-7/Vector) for EMSA.  
NRE4, a concatemer of strong SATB1-binding sites in the NRE, was used as a probe.  
Nuclear extracts from Jurkat cells that express endogenous SATB1 were used as a 
positive control, whereas nuclear extracts from HC11 cells that do not express 
endogenous SATB1 were used as a negative control.  The identities of the shifted 
bands from the MCF-7/SATB1 nuclear extracts were verified by antibody ablation 
assays.  SATB1-specific antibody abolished SATB1 binding to the NRE4 probe, while 
CDP-specific antibody did not. 
 





























Fig. 10.  DOX suppresses expression of transiently transfected MMTV-luciferase 
plasmids in MCF-7/Tet-off cells. 
 MCF-7/Tet-off cells were transiently transfected with pMTV-LUC reporter 
plasmid.  The cells were incubated in the presence or absence of DOX for 24 hr and 
protein extracts were assayed for luciferase activity.  The data represent means ± 
standard deviations of three independent transfections.  The luciferase activities of 
samples obtained from cells grown without DOX were set to 100, and the luciferase 
activity of the second sample using the same amount of protein extract was determined 






































Fig. 11. SATB1 suppresses transiently transfected MMTV-reporter plasmids in 
MCF-7/SATB1 clones. 
 (A) Each clone stably transfected with SATB1 or vector was transiently 
transfected with a constant amount of pMTV-LUC reporter plasmid. The transfected 
cells were maintained in the absence of DOX for 48 hr to induce SATB1.  All the 
SATB1-expressing clones, except clone #10 (C.10), showed decreased luciferase 
activity compared to a clone expressing the empty vector.  The data represent the 
means ± standard deviations of three independent transfections. (B) Western blotting 
of protein extracts and incubation with SATB1 or actin-specific antibody (upper and 
lower panels, respectively). 
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 The dose dependence of SATB1 effects on pMTV LTR-reporter expression was 
determined.  Expression levels of SATB1 can be controlled in MCF-7/SATB1 cells by 
the DOX concentration in some clones; however, since DOX itself affected MMTV 
expression in these cells (Fig. 10), this method could not be used.  Therefore, both the 
SATB1 expression construct and the pMTV-luciferase reporter plasmid were transiently 
transfected into MCF-7 cells.  Various amounts of SATB1 expression construct were 
transfected with a constant amount of the pMTV-LUC plasmid in MCF-7 cells, and the 
empty vector was used to maintain constant levels of transfected DNA.  SATB1 
overexpression resulted in up to 30-fold suppression of transiently transfected MMTV-
luciferase activity in a dose-dependent manner (Fig. 12A).  Western blot analysis 
showed that SATB1 expression increased concurrently with the amount of the SATB1 
expression plasmid (Fig. 12B). 
 The MMTV LTR promoter can be induced by binding of glucocorticoid hormone 
receptor complex to the hormone-responsive element (HRE) (226).  Therefore, the 
ability of SATB1 to suppress glucocorticoid-induced pMTV transcription was 
determined.  The SATB1 or empty expression vector was co-transfected with MMTV-
LUC into MCF-7 cells by electroporation.  After 24 hr, the growth medium was 
supplemented with the hormone dexamethasone (DEX) (10-6 M) for an additional 24 hr 
to induce luciferase expression.  SATB1 suppressed reporter gene expression both in 
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Fig. 12. SATB1 suppresses transiently transfected MMTV reporter gene 
expression in a dose-dependent manner. 
(A) Increasing amounts of SATB1 expression plasmid (0, 2, 15, 30µg) were co-
transfected in MCF-7 cells with a constant 20µg of MMTV-Luciferase reporter gene by 
electroporation.  The empty vector was added to maintain a constant amount of total 
DNA.  SATB1 overexpression suppressed luciferase activity 30-fold compared to the 
activity of empty-vector-transfected cells.  The data represent means ± standard 
deviations of three independent transfections.  (B) A Western blot using SATB1 
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Fig. 13.  SATB1 overexpression represses the luciferase activity of transiently 
transfected MMTV-reporter plasmids in the presence and absence of DEX. 
 MCF-7 cells were transiently co-transfected with SATB1 or empty vector and an 
MMTV-luciferase reporter plasmid and incubated for 24 hr.  The transfected cells were 
incubated with or without DEX for an additional 24 hr, and the luciferase activity was 
measured.  DEX increased expression from the MMTV LTR-luciferase reporter 
approximately 5-fold.  However, SATB1 suppressed MMTV expression in the absence 
and presence of DEX approximately 3-fold and 7-fold, respectively. 
 
 
 To further study the function of SATB1 in transcriptional repression, a series of 
deletion mutants was constructed (Fig. 14).  Four N-terminal, three internal, and four C-
terminal deletions were prepared based on the known domain structure of SATB1.  
The SATB1 N-terminus has a proposed PDZ-like domain involved in protein 
dimerization (amino acids 90 to 204) as well as the recruitment of HDAC (68,218).  
SATB1 has several DNA-binding domains (DBDs), including two Cut repeat domains 
(CR1 and CR2) and an atypical homeodomain (52,149).  To verify expression of all 
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mutant proteins, MCF-7 cells were transfected with the wild-type or mutant constructs 
and incubated for up to 48 hr.  Whole-cell protein extracts were prepared and analyzed 
by Western blotting with a polyclonal antibody, which recognizes the N-terminal  10 
amino acids of SATB1 (Fig. 15A), or a mouse monoclonal antibody, which recognizes 
the SATB1 C-terminus (amino acids 550-667) (Fig. 15B).  Most constructs, except for 
SATB1(1-224) and SATB1(510-764), were expressed at levels comparable to wild-type 
SATB1. 
The deletion mutants were used to determine the specificity of SATB1-
mediated repression of the MMTV LTR in transient assays.   The pMTV-LUC 
expression plasmid was co-transfected into MCF-7 mammary cells with plasmids 
expressing wild-type or mutant SATB1 proteins or the empty vector.  As expected, 
wild-type SATB1 suppressed luciferase expression 10-fold. Surprisingly, all of the 
deletion constructs, including those missing the major DNA-binding domain (MAR 
domain), repressed luciferase expression from the MMTV LTR relative to that observed 
for the empty vector (Fig. 16).  Similar results were obtained when another cell line, XC 
rat fibroblasts, were used (data not shown).  These results suggest that DNA binding is 
not required for the SATB1-mediated transcriptional repression observed with 
unintegrated DNA templates, and that this repression is non-specific, perhaps due to 








































Fig. 14. Schematic diagram of SATB1 and deletion mutants. 
 Positions of the dimerization domain, the proposed nuclear matrix targeting 
sequence (NMTS), the MAR-binding domain, the Cut-like repeats (CR1 and CR2), and 
the homeodomain are indicated.  The numbers in the N-terminal or C-terminal deletion 
constructs indicate the amino acids present in the construct, while the numbers in the 
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Fig. 15. Expression of wild-type and mutant SATB1 proteins. 
 MCF-7 human mammary cells were transfected with wild-type or mutant SATB1 
expression vectors and incubated for 24 to 48 hr prior to preparation of whole cell 
extracts.  (A) Western blotting of protein extracts with polyclonal anti-SATB1 sera 
specific for the N-terminus.  (B) Western blotting of protein extracts with monoclonal 
SATB1 antibody specific for the C-terminus.  Arrowheads in (A) show the expected 
size of SATB1 mutants.  Lower panels in (A) and (B) show Western blotting with actin-





















































































































Fig. 16. DNA binding is not required for SATB1-mediated repression of the MMTV 
LTR from unintegrated templates. 
 Wild-type and mutant SATB1 expression plasmids or the empty vector were co-
transfected with pMTV-LUC into MCF-7 cells in triplicate.  After 48 hr, cytoplasmic 
extracts were prepared and a constant amount of protein was assayed for firefly 
luciferase activity.  Results from vector-transfected cells were assigned a value of 100, 
and all other results are reported relative to 100. 
 
 
3.1.2 SATB1 specifically represses transcription of integrated MMTV LTR-
reporter plasmids and MMTV proviruses. 
 Integrated MMTV proviruses contain LTRs that are organized as a phased 
nucleosomal structure, which is absent from transiently transfected constructs 
containing the MMTV LTR (7,144).  The response of the phased nucleosomal LTR 
structure to cAMP and transcription factors clearly is different from that present on 
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transiently introduced DNA (7,144).  SATB1 has been proposed to function through 
HDAC recruitment and chromatin reorganization (218). Therefore, the response to 
SATB1 of templates containing integrated MMTV LTRs was assessed. 
 XC cells stably transfected with an MMTV LTR-luciferase construct (XC/MTV-
LUC) were used for SATB1 overexpression experiments.  To determine the effects of 
SATB1 on the stably integrated reporter gene, SATB1 must be expressed in a high 
percentage of the cells; if the percentage of expressing cells is low, the effects would 
be diluted by the luciferase activity of cells lacking SATB1 expression.  The MigR1 
retroviral expression vector system was chosen since it has successfully been used to 
give expression in >90% of infected cells. 
 The full-length SATB1 cDNA was cloned into the MigR1 vector and transiently 
transfected into 293T cells together with the gag-pol (pHIT 60) and env (pHIT G) 
expression vectors.  The MigR1 vector lacking an insert was used to produce control 
virus.   Virus particles were collected from the growth medium, concentrated by 
ultracentrifugation, and the virus titer was determined by FACS analysis.  The MigR1 
vector has an IRES-GFP cassette located downstream of the multiple cloning site so 
that GFP-positive cells indicate that cells have been transduced.  Equal titers of virus 
were used for infection of XC/MTV-LUC cells.  Vector-transduced and SATB1-
transduced cells had comparable transduction efficiencies (93% and 94%, 
respectively). 
 As expected, addition of glucocorticoids gave a 7 to 8-fold increase in 
expression from the MMTV LTR in vector-transduced cells.  However, surprisingly, 
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SATB1 suppressed MMTV LTR-luciferase activity 2-fold in the presence of DEX, but 
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Fig. 17. SATB1 suppresses expression from the integrated MMTV LTR in the 
presence of glucocorticoids in XC rat cells. 
 XC cells stably transfected with an pMTV LTR-reporter plasmid were 
transduced with MigR1 or MigR1-SATB1 (MOI=2).  The transduction efficiency was 
>90% in both cases.  The luciferase values are indicated relative to a value of 100 
assigned to vector-transfected cells in the absence of glucocorticoids. 
 
 
 To determine the dose dependence of SATB1-mediated MMTV repression, 
XC/MTV-LUC cells were transduced at two different MOIs.  Suppression by SATB1 
increased using a higher MOI (Fig. 18A), but only was observed in the presence of 
glucocorticoids.  SATB1 suppressed luciferase expression 2.6-fold at MOI=2 and 4.4-
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fold at MOI=8, and this difference was statistically significant.  Western blotting 
confirmed that the higher MOI gave increased SATB1 expression relative to levels of 
actin (Fig. 18B).   
 A similar approach was used to determine the effect of SATB1 overexpression 
in XC rat cells infected by wild-type MMTV (also called XC/C3H).  Rat cells lack 
endogenous MMTV sequences, which might complicate the analysis.  XC/MMTV cells 
were transduced with MigR1 or MigR1-SATB1, incubated in the presence or absence 
of DEX for 24 hr, and then total RNA was extracted.  Semi-quantitative reverse 
transcription (RT)-PCR using gag-specific primers revealed MMTV expression in the 
vector-transduced, but not SATB1-transduced cells, consistent with SATB1 
suppression of MMTV RNA levels (Fig. 19A).  However, gag-pol mRNA levels in 
vector- and SATB1-transduced cells were similar in the absence of DEX (Fig. 19B).  
Viral RNA expression was normalized to gapdh RNA levels in each reaction. 
 To determine the effect of SATB1 on MMTV expression more quantitatively, 
RNase protection assays (RPAs) were performed. MigR1 or MigR1-SATB1 particles 
were transduced into XC/MMTV cells to give transduction efficiencies greater than 90%.  
Cells were grown in the presence or absence of glucocorticoids for 24 hr prior to 
extraction of total RNA.  RNA was hybridized simultaneously with RNA probes specific 
for MMTV and gapdh and then digested with RNase A and T1.  After normalization to 
gapdh RNA levels, SATB1 suppressed MMTV expression 2.8-fold in the presence, but 
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Fig. 18. SATB1 suppresses stably transfected MMTV LTR-luciferase expression 
in a dose-dependent manner. 
 XC/MTV-LUC cells were transduced with MigR1 or MigR1-SATB1 virus at an 
MOI=2 or MOI=8 as indicated.  (A) SATB1-mediated suppression of MMTV LTR 
expression is observed only in the presence of glucocorticoids.   The luciferase values 
were reported relative to a value of 100 for vector-transduced cells at MOI=2.  (B) 
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Fig. 19.  SATB1 suppresses expression of integrated MMTV proviruses in XC 
cells in the presence of DEX. 
 XC/MMTV cells were transduced with MigR1 or MigR1-SATB1.  Total RNA was 
extracted and subjected to semi-quantitative RT-PCR with gag-specific primers and 
different amounts of cDNA (indicated in microliters above each lane). RT-PCR with 
gapdh-specific primers was used to normalize for the amount of RNA in each reaction. 
(A) MMTV gag-pol mRNA expression in the presence of glucocorticoids. (B) MMTV 
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Fig. 20.  RPAs indicate that SATB1 represses MMTV RNA expression in XC cells 
only in the presence of glucocorticoids. 
 XC/MMTV cells were super-infected with MigR1 or MigR1-SATB1 and then 
grown in the presence or absence of 10-6 M DEX for 24 hr.  Total RNA was extracted 
and used for an RPA with an MMTV LTR-specific probe.   The numbers below the 
figure indicate the ratio of MMTV RNA in MigR1-transduced cells relative to MigR1-
SATB1-transduced cells after normalization for gapdh RNA levels.  Ratios were 
calculated independently for cells treated with or without DEX. 
 
 
 The observation that SATB1 affects MMTV RNA levels in rat XC cells only in 
the presence of glucocorticoids is not consistent with previous studies of MMTV 
expression (25,124).  To determine if the results in XC cells are consistent with SATB1 
effects in other cells, a mouse T-cell line (BW5147) and mouse mammary epithelial cell 
line (HC11) were examined.  Both BW5147 and HC11 were stably transfected with 
pMTV-LUC following hygromycin selection to give BW5147/MTV-LUC and HC11/MTV-
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LUC.  Cells were transduced with either MigR1 or MigR1-SATB1 virus to give greater 
than 90% transduction efficiencies (data not shown) prior to growth in the presence 
and absence of DEX.  Western blotting confirmed SATB1 overexpression (Fig. 21C). 
Unlike the XC cells, SATB1 suppressed pMTV LTR-luciferase expression in both the 
mouse T-cell and mammary cell lines, regardless of the presence of glucocorticoids 
(Figs. 21A and B).  However, HC11 cells showed greater suppression of luciferase 
expression than that observed in BW5147 cells, probably because HC11/SATB1 cells 
had higher relative levels of SATB1 expression. 
 These results suggested that the level of SATB1 in transduced cells might 
affect the ability of SATB1 to repress MMTV transcription in XC cells in the absence of 
glucocorticoids.  To test this idea, XC/MTV-LUC cells were transduced with MigR1 and 
MigR1-SATB1 at a higher MOI.  Again, SATB1 repression of MMTV LTR-luciferase 
expression was observed only in the presence of DEX (data not shown).  These data 
suggest that XC cells have a specific defect in their ability to respond to SATB1 in the 












































































Fig. 21.  SATB1 represses MMTV LTR-luciferase expression in mouse T-cell and 
mammary epithelial cell lines in the presence and absence of DEX. 
 HC11/MTV-LUC and BW5147/MTV-LUC cells were transduced with MigR1 and 
MigR1-SATB1 viruses at MOI=15 and MOI=30, respectively, prior to growth for 24 hr in 
the absence (A) or presence (B) of 10-6 M DEX.  The data represent the means ± 
standard deviations of three independent luciferase determinations.  The luciferase 
value of MigR1-transduced cells was set to 100, and the values of SATB1-transduced 
cells are expressed relative to 100.  The luciferase activities of cells transduced with 
vector and SATB1 infectious particle in each set are statistically different by the 
Student’s t test (P < 0.01).  (A) SATB1 suppresses MMTV expression in the absence of 
DEX in HC11 and BW5147 cells. (B) SATB1 suppresses MMTV expression in the 
presence of DEX in HC11 and BW5147 cells. (C) Western blot analysis of SATB1 
expression in transduced HC11 and BW5147 cells. 
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3.1.3. The SATB1 DNA-binding domain is required for SATB1-mediated 
repression of transcription from integrated MMTV LTRs. 
 To determine the specificity of SATB1 suppression on the integrated MMTV 
LTR, vectors expressing wild-type SATB1 or a DNA-binding domain mutant (∆DBD) 
[ID(346-494)] or the empty MigR1 vector were transduced into XC cells infected by 
C3H MMTV (XC/MMTV).  Infected cells were treated for 24 hr in the presence or 
absence of glucocorticoids, and then extracted for total RNA.  As expected, the wild-
type SATB1 gave ca. 2-fold suppression of reporter gene expression relative to that 
from MigR1-transduced cells (Fig. 22).  Deletion of the major SATB1 DBD relieved 
suppression of SATB1-mediated repression of transcription in the presence, but not the 
absence, of glucocorticoids.   This experiment was repeated in HC11 mammary cells 
containing an integrated MMTV LTR-reporter gene (Fig. 23).  Similar to results with XC 
cells, SATB1 suppressed expression from the LTR in the presence of DEX, and this 
suppression was relieved by deletion of the major DNA-binding domain. However, 
unlike experiments in XC cells, SATB1-mediated repression was observed in the 
presence or absence of DEX.   These data indicate that DNA binding is required for 



















































Fig. 22. DNA binding is required for SATB1-mediated repression of expression 
from integrated MMTV proviruses in XC cells. 
 XC/MMTV cells were transduced with MigR1-SATB1, MigR1-∆DBD [ID(346-
494)], or MigR1 virus.  After transduction, half of the cells were treated for 24 hr with 
10-6 M DEX.  Total RNA was extracted for RNase protection assays using an MMTV 
LTR probe.  A portion of the cells also was used for protein extracts.  (A) RNase 
protection assays of RNA extracted from MMTV-infected cells transduced by viruses 
expressing wild-type and mutant SATB1 proteins. RNA was obtained from cells grown 
in the presence (lanes 4 to 6) or absence (lanes 8 and 9) of DEX; the amounts used for 
hybridization were 15 µg RNA from hormone-treated cells and 70 µg RNA from 
untreated cells.  The positions of full-length and protected MMTV and cyclophilin 
(control) probes are shown by arrows.  The ratio of MMTV to cyclophilin RNA 
expression was determined by phosphorimaging.   (B) Western blotting of wild-type 


















































Fig. 23. DNA binding is required for SATB1-mediated repression of MMTV LTR-
reporter gene expression in HC11 cells. 
 HC11/MTV-LUC cells were transduced with MigR1-SATB1, MigR1-∆DBD, or 
MigR1 virus.  After transduction, the cells were expanded for 7 days and treated for 1 
hr with 10-6 M DEX.  (A) Western blotting of wild-type and ∆DBD [ID(346-494)] SATB1 
proteins in transduced cells. (B) The data represent the means ± standard deviations of 
three independent luciferase determinations.  The luciferase value of MigR1-
transduced cells without hormone induction was set to 100, and the values of SATB1-
transduced cells are expressed relative to 100.  The luciferase activities of cells 
transduced with vector, SATB1, and ∆DBD infectious particle in each set of in the 
presence and absence of DEX are statistically different by the Student’s t test (P<0.01). 
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3.1.4. Knock-down of endogenous SATB1 levels in Jurkat T cells elevates MMTV 
expression. 
 The Jurkat human T-cell line has high endogenous levels of SATB1 (Fig. 6).  
Therefore, the small-interfering (si) RNA technique was used to determine if reduction 
of SATB1 levels in these cells would elevate MMTV expression.  Jurkat cells were 
stably transfected with the MMTV-LUC expression plasmid and then incubated with 
600 nM SATB1-specific siRNAs or a non-targeting siRNA in the presence of 
glucocorticoids.  After 60 hr, cells were analyzed by Western blotting and for luciferase 
activity (Fig. 24).  Western blotting revealed approximately 3-fold suppression of 
SATB1 levels in cells treated with the targeting siRNA versus cells treated with the 
non-targeting siRNA (Fig. 24A).  Moreover, treatment with the SATB1-specific siRNA 
increased MMTV LTR-luciferase levels ca. 1.5-fold relative to that from cells treated 
with the non-targeting siRNA (Fig. 24B).  These data are consistent with previous 
SATB1 overexpression experiments indicating that SATB1 represses transcription from 





























































Fig. 24.  Knock-down of endogenous SATB1 expression elevates MMTV 
expression in Jurkat/MTV-LUC cells. 
 Jurkat/MTV-LUC cells were electroporated with 600 nM SATB1-specific siRNA 
or a non-targeting siRNA. Mock treatment consisted of electroporation in the absence 
of siRNA.  Cells were incubated for 60 hr prior to preparation of protein extracts. (A) 
Western blotting with SATB1-specific monoclonal antibody (upper panel) shows 
decreased SATB1 levels relative to actin levels (lower panel) after specific siRNA 
treatment. (B) SATB1-specific siRNA treatment leads to increased luciferase 
expression from the MMTV LTR.  Luciferase levels in cells treated with the non-
targeting siRNA were assigned to a value of 100, and values determined for the same 
amount of protein in other samples are given relative to 100.  Values are means of 
triplicate determinations ± standard deviation.  The luciferase activities of cells treated 
with control and SATB1-specific siRNAs are statistically different by the Student’s t test 
(P<0.01). 
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3.2 THE DOMAIN STRUCTURE OF SATB1 
 The previous section used overexpression and knock-down experiments to 
show that SATB1 functions to suppress transcription from integrated templates 
containing the MMTV LTR.  In this section, the previously described DNA-binding and 
dimerization domains of SATB1 were verified, and several new protein localization 
domains were defined. 
 
3.2.1. Domain requirements for SATB1 binding to the MMTV NRE. 
 Previous data indicated that the major domain required for SATB1-binding to 
DNA encompassed the MAR-binding domain (52).  The dimerization domain from 
amino acids 90 to 204 also was required for DNA binding (68).  To test the ability of 
SATB1 deletion mutants to bind DNA, nuclear extracts were prepared from cells that 
had been transfected with wild-type and mutant SATB1 plasmids.  Nuclear extracts 
were then used in EMSAs with the promoter-proximal NRE4 probe, which has four 
repeats of the strong SATB1 binding site located between -287 and -265 in the MMTV 
LTR (124).  The related transcription factor, CDP, appears to have a weaker affinity for 
this probe (124). 
 As anticipated, wild-type SATB1 showed binding to the NRE probe (Fig. 25, 
lane 3), and at least two DNA-protein complexes were observed.  The C-terminal 
truncation mutants (1-224, 1-274, and 1-345), which lack the MAR domain, CR1, CR2, 
and the homeodomain, did not bind DNA (lanes 4-6). Internal deletions ID(346-494) 
and ID(274-410) missing the MAR domain also had no detectable DNA binding.  The 
N-terminal deletion mutants, SATB1(168-764), (274-764), and (510-764) did not bind 
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NRE4, consistent with previous data that the dimerization domain is required for 
SATB1 binding to DNA (68). Notably, SATB1(55-764) showed reduced binding to the 
NRE, particularly the lower mobility complex, suggesting that this mutation may affect 
the efficiency of protein multimerization.  An internal deletion mutant, ID(224-278), had 
approximately wild-type DNA-binding activity (compare lanes 3 and 8), although the 
intensity of the lower mobility complex was increased compared to the wild-type protein.  
SATB1(1-494), which contains both the MAR-binding and dimerization domains, 
showed limited binding to the NRE4 probe. 
To determine the identity of complexes formed with the MMTV NRE, we used 
antibody ablation experiments (Fig. 26).  Anti-SATB1, but not preimmune serum, 
abolished NRE binding of all SATB1-specific complexes observed.  The nuclear extract 
of Jurkat cells, which express high levels endogenous SATB1, was used for a positive 
control.  The results showed that endogenous SATB1 and SATB1 in MCF-7 cells 
migrated similarly (Fig. 26, lanes 12-15), and the observed bands were abolished by 
SATB1-specific antibody.  Similar results were observed when the rat fibroblast cell line, 














































































Fig. 25. Dimerization and MAR-binding domains are required for SATB1 binding 
to the MMTV NRE. 
 EMSAs using extracts from cells expressing wild-type and mutant SATB1 
proteins. Nuclear extracts were prepared from MCF-7 human mammary cells 
transfected with SATB1 expression plasmids.  Extracts then were used in gel shift 
assays with NRE4 probe, a four-repeat concatamer of strong SATB1-binding sites in 
the MMTV NRE.  Lane 1 contains the labeled probe in the absence of added nuclear 
extract, whereas lane 2 shows probe binding to nuclear extracts transfected with the 
empty vector.  Gel shifts with nuclear extracts obtained from transfections with wild-
type SATB1 (lane 3) or various mutants (lanes 4 to 14) are shown.  A bracket shows 
the distribution of various SATB1-specific complexes. 
 











































































Fig. 26. Antibody ablation assays reveal the identity of the retarded bands. 
 Even-numbered lanes indicate assays performed in the presence of preimmune 
sera and odd-numbered lanes (except lane 1) indicate assays performed in the 
presence of SATB1-specific rabbit polyclonal antibody. Gel shifts with nuclear extract 
from human Jurkat T cells (lanes 12 and 13) were used as a positive control. Lanes 2-
11, 14 and 15 contain nuclear extract from transfected MCF-7 cells.  Gel shifts shown 
in lanes 4 and 5 and lanes 14 and 15 were performed using nuclear extracts from 
different transfections with wild-type SATB1. 
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3.2.2. Subnuclear localization of SATB1 and deletion mutants. 
 SATB1 previously has been shown to be a nuclear protein with MAR-binding 
activity (50).  To determine the subnuclear distribution of SATB1, confocal microscopy 
was performed in conjunction with staining for lamin B, a nuclear matrix protein (88).  A 
GFP-SATB1 fusion construct was prepared and transfected into MCF-7 cells grown on 
glass cover slips.  Cells were fixed, permeabilized, and stained with lamin B-specific 
antibody.  The primary antibody then was detected by incubation with a rhodamine-
conjugated secondary antibody. 
 GFP-SATB1 was diffusely localized inside the nucleus, with the exception of 
the nucleolus, whereas lamin B was largely concentrated at the inner surface of the 
nuclear membrane.  A merged image showed that SATB1 overlaps the inner half of the 
ring structure formed by lamin B (Fig. 27).  Since lamin B is a major component of the 
nuclear matrix (88), these results suggested that a portion of wild-type SATB1 was 
associated with the nuclear matrix.   
 To test whether the nuclear matrix association of SATB1 is determined by a 
particular protein domain, wild-type SATB1 and deletion mutants were analyzed by 
biochemical fractionation.  To validate this method, MCF-7 cells were fractionated into 
soluble, chromatin, and nuclear matrix fractions based on the procedure of He et al. 
(50,111).  The soluble fraction (SF) contains cytosolic and soluble nuclear proteins, the 
chromatin (CH) fraction contains proteins that tightly associate with chromatin, and the 
nuclear matrix (NM) fraction contains nuclear matrix and membrane-bound proteins.  
To verify the efficiency of the method, fractions were subjected to Western blotting and 
incubation with antibodies specific for lamin B, histone H1, and cytochrome C (a 
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mitochondrial protein) (152) (Fig. 28).  As expected, lamin B, histone H1, and 
cytochrome C were detected only in the nuclear matrix, chromatin, and soluble 





Fig. 27. SATB1 is a nuclear protein that partially colocalizes with lamin B. 
 MCF-7 cells grown on glass cover slips were transfected with GFP-SATB1 
expression plasmid and incubated for 24 hr.  Cells then were fixed with 4% 
paraformaldehyde and permeabilized with 0.1% Triton X-100.  Cells were stained with 
lamin B-specific antibody, washed, and incubated with secondary antibody conjugated 
with rhodamine.  The cover slips were observed under a Leica TCS4D confocal 
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Fig. 28. Subcellular fractionation of various endogenous cellular proteins. 
 MCF-7 cells were incubated with Triton X-100 in CSK buffer to extract soluble 
cytoplasmic and nuclear proteins (SF).  The insoluble fraction was treated with DNase I 
to remove DNA, and soluble chromosome-bound proteins were obtained (CH).  The 
remaining insoluble proteins were washed extensively with 2 M NaCl, and then 8M 
urea was added to obtain the nuclear matrix fraction (NM).  Fractions were resolved on 
SDS-containing 10% polyacrylamide gels and subjected to Western blotting.  Blots 
were incubated with antibodies specific for lamin B (upper panel), histone H1 (middle 
panel), or cytochrome C (lower panel). 
 
 
 To determine the subcellular localization of SATB1 deletion mutants, MCF-7 
cells were transfected with wild-type and mutant constructs and subjected to 
biochemical fractionation (Fig. 29).  Each fraction was subjected to Western blotting 
with SATB1-specific antibody.  Wild-type SATB1 localized in relatively equal 
proportions to the soluble, chromatin and nuclear matrix fractions. However, SATB1(1-
494), missing the entire C-terminus of the protein, redistributed so that none of the 
protein localized in the soluble fraction.  Further C-terminal deletion to amino acid 274 
gave a protein that remained associated with the nuclear matrix, although the amount 
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in the matrix appeared to be diminished.  However, the mutant SATB1(1-224) 
appeared to be localized entirely to the soluble fraction.  These results implicated 
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Fig. 29.  Subcellular localization of wild-type and mutant SATB1 proteins. 
 SATB1 wild-type and mutant proteins were transfected into MCF-7 cells, 
incubated for 24 to 48 hr, and fractionated.  Equal amounts of each fraction were 
separated on denaturing polyacrylamide gels and subjected to Western blotting.  
Extracts from the internal and N-terminal deletion mutants were incubated with 
monoclonal SATB1-specific antibody, whereas extracts from cells transfected with the 
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 Because the biochemical fractionation of He et al. (81) does not distinguish 
between soluble cytoplasmic and nuclear proteins, immunofluorescence microscopy 
was used to verify that the loss of nuclear matrix association by the mutant SATB1(1-
224)  protein was not due to failure to localize to the nucleus.  MCF-7 cells were 
transfected with the mutant construct and cultured for approximately 48 hr.  Cells then 
were fixed, incubated with polyclonal anti-SATB1 sera, washed, and incubated with 
specific secondary antibodies and DAPI. Results of these experiments indicated that 
the mutant SATB1 was co-localized with the DAPI-stained nuclei (Fig. 30).  These data 
indicate that the N-terminal 224 amino acids of SATB1 contain a nuclear localization 
signal (NLS), but not an NMTS. 
 
Phase Contrast Anti-SATB1 DAPI  
 
Fig. 30. The SATB1 mutant (1-224) is localized to the nucleus. 
 MCF-7 cells were grown on glass discs, transfected with SATB1(1-274) 
expression vector and incubated for 48 hr.  The cells were fixed with 4% 
paraformaldehyde in PBS, permeabilized, and stained with SATB1-specific polyclonal 
antibody.  The cells then were incubated with FITC-labeled anti-rabbit IgG.  DAPI 
staining was used to localize the nuclei. 
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 A series of N-terminal deletion mutants were tested to confirm the localization 
of an NMTS to the SATB1 region between amino acids 224 to 278 (Fig. 29).  The 54 N-
terminal amino acids, which have been reported to be cytotoxic in yeast (68), were 
deleted.  However, this mutant (55-764), localized similar to that of wild-type SATB1.  
Further deletions to amino acids 168 or 275 greatly reduced chromatin and nuclear 
matrix association, consistent with an NLS in this region.  The mutant SATB1(275-764) 
appeared to have no nuclear matrix association, consistent with an NMTS localized 
between amino acids 224 to 278.  Furthermore, fluorescent microscopy showed that 
nuclear localization of SATB1(168-764) was reduced compared to wild type SATB1 
although the deletion did not completely abolish its nuclear localization (data not 
shown).  
 Internal deletion (ID) mutants also were constructed to aid localization of 
SATB1 regions that determine nuclear matrix association.  ID(224-278), which deletes 
the putative NMTS, significantly reduced, but did not abolish, the nuclear matrix 
localization of SATB1 (Fig. 29).  Similarly, examination of the mutants ID(274-410) and 
ID(346-494) suggested that deletion of the major DNA-binding domain also reduced 
nuclear matrix association.  These data suggest that SATB1 may contain multiple 
nuclear matrix localization sequences.  Because the major DNA-binding domain is 
required independently for SATB1-mediated transcriptional repression, the NMTS 
between amino acids 346 and 494 was not further characterized.  Additional 
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3.2.3. A SATB1 NMTS is localized between amino acids 224 and 278. 
 To specifically determine whether the SATB1 NMTS targets non-nuclear matrix 
proteins to the nuclear matrix, GFP and LexA were independently fused to SATB1 
sequences between amino acids 224 and 278 (GFP-NMTS and LexA-NMTS).  The 
fused and unfused constructs were transfected into MCF-7 cells, and protein 
localization was analyzed by biochemical fractionation.  GFP, which lacks an NLS (77), 
localized primarily to the soluble fraction.  However, the fusion protein GFP-NMTS was 
distributed to the soluble, chromatin, and nuclear matrix fractions similar to wild-type 
SATB1 (Fig. 29 and 31).  On the other hand, LexA, which has an NLS (186), localized 
to both the soluble and chromatin fractions.  The LexA-NMTS fusion again showed 
relocalization of a fraction of the protein to the nuclear matrix.   
 To quantitate the effect of the NMTS on nuclear matrix association, Western 
blotting of fractions obtained from cells transfected with plasmids expressing GFP or 
various GFP-fusion proteins was performed (Fig. 32).  The amount of these proteins in 
different fractions was determined using the Odyssey imaging system and compared to 
that of a known nuclear matrix protein, lamin B.  At least 90% of lamin B was detected 
in the nuclear matrix in multiple sample preparations, whereas only 3% of GFP was in 
this fraction.  However, 42% of GFP-NMTS containing SATB1 amino acids from 224 to 
278 associated with the nuclear matrix, a 14-fold increase.  GFP-SATB1(1-55) 
containing the first 55 amino acids of SATB1 showed no increased association with the 
nuclear matrix compared to GFP alone, whereas GFP-SATB1(1-224) showed a 4-fold  
increase in association with the nuclear matrix compared to GFP.  The latter 
observation may result from increased GFP localization to the nucleus due to the NLS 
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or to weak NMTS activity of these sequences or both.  Nevertheless, these results 
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Fig. 31. A SATB1 NMTS targets heterologous proteins to the nuclear matrix. 
 The GFP, LexA, GFP-NMTS, and LexA-GFP expression constructs were 
transfected into MCF-7 cells.  After 24 to 48 hr, cells were fractionated into soluble (SF), 
chromatin (CH), and nuclear matrix (NM) fractions.  Fractions were separated on 
denaturing polyacrylamide gels and subjected to Western blotting.  Blots were 
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Fig. 32. Quantitation of nuclear matrix association of GFP-SATB1 fusion proteins. 
 Plasmids encoding GFP or GFP-SATB1 fusion proteins were transfected into 
MCF-7 cells, incubated for 24 to 48 hr, and fractionated. Fractions were analyzed by 
Western blotting and incubation with GFP or lamin B-specific antibodies.  Alexa Fluor 
680-conjugated rabbit Ig-specific or IRDye800-conjugated goat Ig-specific antibodies 
were used to detect bands.  Band intensities were measured using the Odyssey 
imaging system. The total amount of fluorescence in the soluble, chromatin, and 
nuclear matrix fractions was set to 100. The small numbers below each figure indicate 
the percentage of fluorescence of either GFP or lamin B present in each fraction. The 
whole cell lysate (WL) represents the amount of protein in one-quarter of the 
unfractionated transfected cells after sonication. 
 
 
Confocal microscopy was used to confirm the biochemical fractionation 
experiment.  MCF-7 cells grown on glass discs were transfected with LexA- or LexA-
NMTS expression constructs.  Transfected cells then were subjected to nuclear matrix 
preparation on the discs and then incubated with LexA-specific antibody.  After 
washing, cells were then incubated with FITC-conjugated secondary antibody.  The 
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number of cells transfected with LexA or LexA-NMTS was comparable.  However, only 
LexA-NMTS was observed after extraction, consistent with the ability of the NMTS to 
direct LexA to the nuclear matrix (Fig. 33).  Together with the biochemical fractionation, 
these data indicate that the SATB1 amino acids between 224 and 278 act as a nuclear 








Fig. 33. The SATB1 NMTS promotes retention of LexA in the nuclear matrix. 
 MCF-7 cells grown on glass discs were transfected with LexA or LexA-NMTS 
expression vectors.  Cells were incubated for 24 hr and nuclear matrix was prepared in 
situ.  Subsequently, these preparations were incubated with LexA- and lamin B-specific 
antibodies prior to staining with FITC-conjugated mouse-specific and rhodamine-
conjugated goat-specific secondary antibodies.  Confocal microscopy was used to 
detect independent or merged images of the two fluorescent antibodies. 
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One explanation for the observed results is that the defined NMTS of SATB1 
contains an NLS, leading to additional association of GFP-NMTS with the nuclear 
matrix.  To eliminate the possibility, localization of a SATB1 NLS was confirmed by 
fluorescent microscopy of cells expressing wild-type and mutant SATB1 proteins fused 
to GFP (Fig. 34).  GFP alone is localized throughout the cell, whereas GFP-SATB1 
was strictly nuclear with a slightly punctate appearance.  Linkage of the first 55 amino 
acids of SATB1 to GFP resulted in slightly more nuclear localization compared to GFP 
alone, but fusion to the N-terminal 224 amino acids had an exclusively nuclear 
punctate appearance as previously described (77).  GFP fusion to SATB1 amino acids 
224-278 (GFP-NMTS) showed a similar localization as GFP alone, suggesting that this 
region lacks an NLS. Since no consensus NLS is localized in the first 224 amino acids 













Fig. 34. Intracellular localization of wild-type and mutant SATB1 fusion proteins 
by fluorescence microscopy.   
HC11 mouse mammary cells were transiently transfected with plasmids 
encoding GFP or GFP fusions to wild-type or mutant SATB1 proteins. After 24 to 48 hr, 
cells grown on glass coverslips were fixed in paraformaldehyde, stained with DAPI and 
viewed under a fluorescence microscope at two different wavelengths. 
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3.3 FUNCTION OF SATB1 NUCLEAR MATRIX BINDING 
 Two different approaches were used to determine the function of the SATB1 
NMTS between amino acids 224 and 228. First, SATB1 constructs lacking the 
NMTS(224-278) were transduced into cells carrying integrated MMTV proviruses or 
integrated MMTV LTR-reporter constructs. These experiments were used to test 
whether the NMTS is critical for the ability of SATB1 to repress transcription from the 
MMTV LTR.  Second, because the NMTS likely interacts with specific cellular proteins 
to exert its function, the NMTS was used as bait in the yeast two-hybrid assay.   
 
3.3.1. Nuclear matrix binding regulates SATB1-mediated transcriptional 
repression. 
 Previous data indicated that specific SATB1 suppression of MMTV transcription 
was demonstrable on integrated, but not transiently transfected, constructs containing 
the MMTV LTR (Fig. 16, 22, and 23).  Thus, stably integrated proviruses in MMTV-
infected XC cells (XC/MMTV) were used to assess the functional effect of NMTS 
deletion.  MigR1, MigR1-SATB1, and MigR1-∆NMTS [previously known as ID(224-
278)] vectors were independently co-transfected into 293T packaging cells with 
plasmids capable of expressing gag-pol and VSV G protein.  The infectious particles 
were concentrated, tittered, and.  XC/MMTV cells were transduced with equal numbers 
of infectious particles containing the empty vector or vectors containing either wild-type 
SATB1 or SATB1∆NMTS.  Cells then were expanded and induced with DEX for 24 hr 
to maximize MMTV expression from the LTR. 
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 Since the MMTV LTR promoter directs expression of the gag-pol mRNA, 
Western blotting was performed to compare the relative expression of MMTV Gag 
protein (Fig. 35).  Expression of wild-type SATB1 significantly suppressed Gag 
expression compared to that produced in the presence of the MigR1 control vector 
(compare lanes 2 and 3, upper panel).  Deletion of the NMTS relieved this suppression.  
Western blotting also revealed that comparable amounts of wild-type and mutant 
SATB1 were expressed (Fig. 35, middle panel).  Actin-specific antibody showed that 
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Fig. 35. Deletion of the NMTS relieves SATB1-mediated repression of Gag 
expression from integrated MMTV proviruses. 
 XC/MMTV cells were incubated for 4 to 5 days post-transduction (MOI=1) and 
then incubated in the presence of 10-6 M DEX for an additional 24 hr.  The transduction 
efficiency was >95% as determined by FACS analysis.  Protein extracts were 
subjected to Western blotting, and blots were incubated with antibodies specific for 
MMTV Gag (upper panel), SATB1 (middle panel), or actin (lower panel).    
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 Because Western blotting is only semi-quantitative, RNase protection assays 
(RPAs) were used to quantitate the effect of NMTS removal on SATB1-specific 
repression.  Again, XC/MMTV cells were transduced with equal amounts of infectious 
particles from MigR1, MigR1-SATB1, and MigR1-∆NMTS.  Over 95% of the cells were 
transduced as determined by FACS analysis.  After establishment of the viral infection, 
cells were treated with DEX for 24 hr to induce MMTV expression, and then total RNA 
was extracted.  RPAs were performed using labeled MMTV LTR and gapdh probes, 
and MMTV RNA levels were quantitated using a phosphorimager after normalization 
for gapdh expression (Fig. 36). Results indicated that SATB1 overexpression reduced 
MMTV transcription by approximately four-fold, whereas the SATB1∆NMTS gave ca. 
three-fold abrogation of this effect (compares lanes 4-6). 
 A similar experiment was performed using rat XC cells that had stably 
integrated copies of an MMTV LTR-luciferase reporter gene (XC/MTV-LUC).  Stably 
transfected cells were transduced with equal numbers of infectious particles containing 
the MigR1, MigR1-SATB1, MigR1-∆NMTS, or MigR1-∆DBD [also known as ID(346-
494)] vectors as described previously.  Transduced cells then were treated with or 
without DEX for 24 hr, and then protein extracts were prepared.  Western blotting 
confirmed similar expression levels of wild-type and mutant SATB1 proteins (Fig. 37A).  
Luciferase assays indicated that wild-type SATB1 expression reduced LTR-directed 
reporter gene expression 5.5-fold in the presence, but not the absence, of DEX (Fig. 
37B).  Deletion of either the NMTS or the MAR-binding domain (DBD) significantly 
relieved this suppression. 
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Fig. 36. Deletion of the NMTS relieves SATB1-mediated repression of the MMTV 
LTR in XC cells in RNase protection assays. 
 XC/MMTV cells were transduced with MigR1, MigR1-SATB1, or MigR1-∆NMTS.  
Four to five days post-infection, 10-6 M DEX was added for 24 hr, and total RNA was 
extracted for RPAs.  RNAs were hybridized to labeled probes specific for the MMTV 
LTR and gapdh.  MMTV expression was quantitated using the phosphorimager and 
normalized to gapdh levels.  Bands proximal to MMTV-specific bands represent 
incompletely digested probe since they also appear in reactions containing RNA from 
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Fig. 37. The NMTS is required for optimal SATB1-mediated repression of the 
MMTV LTR in the presence, but not the absence, of glucocorticoids. 
 (A) Western blotting of wild-type and SATB1 mutants in XC cells expressing a 
stably integrated MMTV LTR-luciferase construct.  Western blots were incubated with 
SATB1- or actin-specific antibodies (upper and lower panels, respectively).  (B) 
Reporter gene assays of XC/MTV-LUC cells expressing wild-type or mutant SATB1 
proteins. The luciferase activity of the same amount of protein from each sample was 
normalized to that of cells transduced with the MigR1 control virus (assigned a relative 
value of 100) (MOI=15). Data are expressed as an average of three independent 
luciferase assays from the same transduction, and error bars represent the standard 
deviations from the means. The luciferase activity of extracts from SATB1-transduced 
cells was significantly different (P<0.01; two-tailed Student’s t test) from that obtained 
with vector-transduced cells.  Results from ∆NMTS or ∆DBD-transduced cells also 
were significantly different from results obtained with SATB1-transduced cells. 
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 Another cell line, HC11 mammary cells stably transfected with MMTV-LUC 
(HC11/MTV-LUC) were used to evaluate the effect of the NMTS of SATB1-mediated 
repression.  HC11/MTV-LUC cells were transduced with the same amounts of MigR1, 
MigR1-SATB1, MigR1-∆DBD, and MigR1-∆NMTS infectious particles.  Approximately 
90% of the cells were transduced.  Following infection, cells were treated with and 
without DEX for 24 hr, and protein extracts were prepared.  Similar amounts of the 
wild-type SATB1 and mutant proteins were produced as detected by Western blotting 
(Fig. 38A).  SATB1 suppressed MMTV expression both in the presence and absence 
of glucocorticoids, and deletion of the NMTS partially relieved this suppression (Fig. 
38B).  As expected, deletion of the major SATB1 DNA-binding domain (MigR1-∆DBD) 
completely abolished SATB1-mediated transcriptional repression from the MMTV LTR.  
Thus, the NMTS appears to be required for maximal effects of SATB1 on the MMTV 
































































Fig. 38. Deletion of the NMTS relieves SATB1-mediated repression from the 
MMTV LTR in mammary cells. 
 (A) Western blot of wild-type and mutant SATB1 proteins in HC11 cells stably 
expressing MMTV-LUC.  SATB1, ∆NMTS, and ∆DBD were ectopically expressed in 
HC11/MTV-LUC cells by transduction (MOI=15).  Cells were then incubated for 24 hr in 
the presence or absence of 10-6 M DEX.  Protein extracts were subjected to Western 
blotting and incubation in the presence of monoclonal SATB1-specific (upper panel) or 
actin-specific (lower panel) antibody.  (B) Luciferase activity of stably integrated MMTV 
LTR-reporter genes in the presence of wild-type or mutant SATB1 proteins.  
HC11/MTV-LUC cells were treated as described in panel A.  Luciferase values were 
calculated as described in Fig. 37.  The luciferase activity of extracts from SATB1-
transduced cells was significantly different (P<0.01; two-tailed Student’s t test) from 
that obtained with control virus-transduced cells (either in the presence or absence of 
hormone).  Results from MigR1-∆NMTS and MigR1-∆DBD-transduced cells (with or 
without hormone) also were significantly different from those obtained with similarly 
treated SATB1-transduced cells.  The entire experiment was repeated with similar 
results. 
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 SATB1 recruits chromatin remodeling complexes containing histone 
deacetylase 1 (HDAC1) to the IL-2Rα locus by directly interacting with HDAC1 (218).  
This result suggests that SATB1 might suppress IL-2Rα expression by modulating 
histone acetylation.  Therefore, an HDAC inhibitor, trichostatin A (TSA), was used to 
test the involvement of HDAC1 on SATB1-mediated LTR repression.  Previous data 
suggested that a low concentration of TSA activates stably integrated MMTV LTR 
expression, while higher concentrations inhibited MMTV transcription.  HC11/MTV-LUC 
cells were transduced with MigR1, MigR1-SATB1, MigR1-∆NMTS, or MigR1-∆DBD 
infectious particles.  Cells then were incubated without TSA or two different TSA 
concentrations for 24 hr.  Interestingly, both concentrations of TSA inhibited MMTV 
expression (up to 2.5-fold) (Fig. 39), suggesting that increased acetylation of a cellular 
factor inhibits basal MMTV transcription.  SATB1 expression reduced the TSA-
mediated suppression. This effect appeared to be specific since the DBD-deletion 
mutant had similar luciferase values as vector-transduced cells.  Surprisingly, NMTS 
deletion potentiated the effect of SATB1 on TSA-mediated suppression.  These data 
suggest that SATB1 may directly or indirectly reduce acetylation of a factor(s) at the 
MMTV promoter, consistent with the ability of SATB1 to recruit HDACs (218).  Deletion 








































Fig. 39. Deletion of the NMTS potentiates the relief of TSA-mediated suppression 
of basal MMTV expression by SATB1. 
 HC11/MTV-LUC cells were transduced with equal amounts of MigR1, MigR1-
SATB1, MigR1-∆NMTS, or MigR1-∆DBD infectious particles (MOI=15).  Transduced 
cells were incubated without TSA or in the presence of 5 or 50 ng/ml TSA for 24 hr.  
Protein extracts were prepared, and equal amounts from each transduction were 
assayed in triplicate for luciferase activity.  Luciferase activities were normalized to that 
of vector-transduced cells grown in the absence of TSA (assigned a value of 100). 
Cellular protein recoveries were similar in the presence or absence of TSA. 
 
 
3.3.2. Cellular factors interacting with a SATB1 NMTS. 
 The previous section established that nuclear matrix binding is critical for 
SATB1-mediated transcriptional repression of the MMTV LTR.  Since the SATB1 
NMTS(224-278) is sufficient to direct fusion proteins to the nuclear matrix (Fig. 31-34), 
interaction with cellular proteins may be responsible for this effect.  Therefore, a yeast 
two-hybrid screen was used to detect cellular proteins that interact with the SATB1 
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NMTS between amino acids 224 and 278.  The NMTS was amplified by PCR and 
cloned into a GAL4 DBD-fusion vector (pGBKT7) to express Myc-tagged GAL4 DBD-
NMTS in yeast.  The yeast strain AH109 was then transformed with pGBKT7 or 
pGBKT7-NMTS, and protein expression was tested by Western blotting (Fig. 40).  A 
construct expressing Myc-tagged GAL4 DBD-p53 protein was used as positive control.  
























1         2         3         4 
 
Fig. 40. GAL4-NMTS fusion protein is expressed in yeast cells. 
 Cell lysates were prepared from yeast cells transformed with constructs 
expresssing pGBKT7 (Myc-tagged GAL4 DBD), pGBKT7-p53 (Myc-tagged GAL4 
DBD-p53), pESC-TRP (untagged GAL4 DBD), and pGBKT7-NMTS (Myc-tagged GAL4 
DBD-SATB1 NMTS).  Lysates were subjected to Western blotting and incubation with 
Myc-specific antibody.  Untagged GAL4-DBD expression construct served as the 
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 Subsequently, the GAL4 DBD and GAL4 DBD-NMTS expressing yeast cells 
were transformed with an expression library derived from human thymus cDNA fused 
to the GAL4 activation domain (AD).  This library was chosen because of the high 
expression levels of SATB1 in thymus (53) and the known effects of SATB1 knockout 
on thymic gene expression (5).  Cells were plated on three-dropout media plates (Leu-, 
Trp-, and His-) to select for retention of the GAL4 DBD and GAL AD plasmids as well 
as a reporter plasmid allowing HIS3 synthesis.  Since the reporter plasmid contains 
GAL4 DNA-binding sites upstream of the promoter, interaction of the GAL4 DBD and 
GAL4 AD on these sites should allow growth on three-dropout plates. Colonies were 
re-plated two more times on three-dropout media to remove false-positive colonies.  
Twenty six positive clones were selected and sequenced.  Interestingly, one of the 
positive clones was lamin A, a major component of the nuclear matrix in some cell 
types (116) (Table 2).  However, none of the clones were detected more than once, 
suggesting that the library screening had not been saturated. 
 
Table 2. Clones selected during a yeast two-hybrid screen  




Gene Name Frequency 
3 BAC RP11-94E10 1 
Actin, beta 1 
Acyl coA synthetase 3 1 
ADP-ribosylation-like factor 6 interacting protein 4 1 
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ADP-ribosyltransferase 1 
APC11 anaphase promoting complex subunit 11 1 
ATP synthase 1 
Break point cluster region (BCR) 1 
Chromosome 1 clone RP11-88N-11 1 
Chromosome 17 clone hRPK, 481-C-4 1 
Chromosome 5 clone CTC-453E13 1 
Clathrin, heavy polypeptide 1 
GlucosidaseI 1 
Glyceraldehyde 3-phosphate-dehydrogenase 1 
Heat shock 60kD protein 1 1 
HS1 binding protein (HAX1) 1 
Immunoglobulin heavy chain constant region gamma2 1 
Lamin A 1 
Nuclear transport factor 2 (NUTF2) 1 
Protease subunit beta type 6 1 
Ribosomal protein S20 1 
Similar to unc-51-like kinase 2 1 
Sn-RNP-specific protein, 116kD 1 
Splicing factor SRp30C 1 
Translation elongation factor 1 alpha 1 1 
Tubulin, beta 5 1 
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B. 
 
Gene Name Frequency 
A disintegrin and metalloproteinase domain 19  
(meltrin beta) (ADAM19) 
1 
Actin, beta 1 
FYN oncogene related to SRC, FGR, YES (FYN) 2 
HLA-B associated transcript 3 (BAT3) 3 
HSPC118 1 
Human splicing factor SRp40-3 1 
Koyt binding protein 1 1 
Ubiquitin-conjugating enzyme, UBCH8 6 
 
 
 Two-step screens were used to identify weak interactions with the SATB1 
NMTS.  Thymic library transformants were plated on two-dropout selection media (Leu-, 
Trp-) to select transformants containing both a GAL4 DBD and a GAL4 AD.   Cells then 
were plated on three-dropout media to identify plasmids that would allow synthesis of 
histidine. Sixteen clones were sequenced and identified (Rachel Misquitta, personal 
communication) (Table 2B), and UBCH8, BAT3, and FYN were identified more than 
once.   No overlap was noted between the two screens. 
 Two clones expressing either UBCH8 or lamin A and a GAL4 DBD-NMTS 
subsequently were co-transformed.  Assays for β-galactosidase activity suggested that 
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both candidate proteins interacted with the SATB1 NMTS (data not shown), and this 
interaction required the presence of both the AD and the DBD expression plasmids. 
 To verify the interaction between SATB1 and lamin A (Table 2A), a co-
immunoprecipitation experiment was performed in 293T cells.  Cells were co-
transfected with expression constructs for wild-type SATB1 and Myc-tagged lamin A or 
Myc-tagged lamin C (Fig. 41).  Lamin A and C differ only at their C-terminus (64).  Cell 
lysates were incubated with antibody to Myc, and precipitates were analyzed by 
Western blotting and incubation with antibodies specific for Myc or SATB1.  Myc-
specific antibody co-precipitated SATB1 as well as both Myc-tagged proteins.  SATB1 
was not precipitated by Myc-specific antibody if Myc-tagged proteins were absent, 
although similar amounts of SATB1 were expressed in both cases. 
Reciprocal experiments also were performed.  GFP-SATB1 and either Myc-
tagged Lamin A or Lamin C expression vectors were co-transfected into 293T cells. 
GFP-specific antibody co-precipitated both lamin A and lamin C, but only in the 
presence of SATB1 overexpression (Fig. 42).  Interestingly, lamin C appeared to co-
precipitate with SATB1 more efficiently than lamin A. 
To determine the specificity of lamin A and C interaction with the NMTS, 293T 
cells were co-transfected with lamin A or C and ∆NMTS.  Co-precipitation experiments 
indicated that SATB1 lacking the NMTS retained interaction with lamin A and C (Fig. 
43).  These data suggest that the interaction between lamins A/C and SATB1 is not 






































Fig. 41. Overexpression of SATB1 in 293T cells allows interaction with lamin A 
and C. 
 Myc-tagged lamin A or C expression plasmids were co-transfected with a 
SATB1-expression vector.  Equal amounts of protein lysates were analyzed directly for 
protein expression by Western blotting with SATB1-specific or Myc-specific antibodies 
(upper two panels, respectively).  Other portions of the same lysates were incubated 
with Myc-specific antibody, and precipitates were collected with protein A/G agarose, 
washed extensively, and analyzed on denaturing polyacrylamide gels.  Western blots 
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Fig. 42. GFP-tagged SATB1 co-precipitates with Myc-tagged lamin A and C. 
 GFP-SATB1 and Myc-tagged lamin A or C expression vectors were co-
transfected into 293T cells.  After 24 hr, transfected cells were lysed and analyzed 
directly by Western blotting with GFP-specific or Myc-specific antibodies (upper two 
panels, respectively).  Another portion of the lysates was incubated with GFP-specific 
antibody and subjected to Western blotting with Myc-specific or GFP-specific 






























Fig. 43. Interaction between lamin A and SATB1 is not specific for the NMTS. 
Myc-tagged lamin A expression plasmid was co-transfected with a GFP-SATB1 
or GFP- ∆NMTSexpression vector.  Equal amounts of protein lysates were analyzed 
directly for protein expression by Western blotting with GFP-specific or Myc-specific 
antibodies (upper two panels, respectively).  Other portions of the same lysates were 
incubated with GFP-specific antibody, and precipitates were collected with protein A/G 
agarose, washed extensively, and analyzed on denaturing polyacrylamide gels.  
Western blots then were analyzed with Myc-specific or GFP-specific antibodies (lower 
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4.  DISCUSSION 
 
4.1 DEVELOPMENT OF AN MMTV REPORTER SYSTEM FOR SATB1 FUNCTION 
SATB1 was cloned by screening a human testis cDNA library using the MAR 
sequence located 3’ of the mouse immunoglobulin µ heavy chain (IgH) enhancer (53).  
SATB1 has been shown to regulate gene expression by binding to the matrix 
attachment regions (MARs) of various genes such as the DNase I-hypersensitive site 
(HS1) in the T cell receptor β locus, the gp91phox promoter region, and the major 
breakpoint region (MBR) of BCL2 (38,80,172).  Two groups have reported that SATB1 
acts as a repressor, whereas others have suggested that SATB1 is an activator of 
gene expression (32,111,115,210).  Subsequently, studies of SATB1-knockout mice 
revealed that 2% of 589 genes surveyed showed altered expression during T-cell 
development.  RT-PCR analysis confirmed that 9 of 10 genes tested had increased 
expression in SATB1-null thymocytes, whereas one gene (TDAG51) had decreased 
RNA levels.   These results suggest that SATB1 is primarily a repressor in the thymus 
(5).  Thymocyte development was blocked mainly at the CD4+CD8+ stage, and 
homozygous knockouts died by 3 weeks of age (5). 
Transcriptional studies of SATB1 have been particularly difficult because of 
problems associated with SATB1 overexpression and lack of a proper reporter system 
in cell culture (38,111).  SATB1 has been reported to bind to MAR sequences within 
the MMTV NREs in the U3 region of the LTR (124).  Mutation of a strong SATB1-
binding site in the promoter-proximal NRE (+924) elevated transcription from the 
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MMTV standard LTR promoter using transient transfection assays, consistent with 
SATB1 as a transcriptional repressor of MMTV expression (25). Moreover, this same 
SATB1 mutation resulted in elevated expression from integrated LTR-reporter 
constructs in the lymphoid tissues of transgenic mice relative to mammary gland (124).  
Therefore, the well-characterized MMTV promoter was used to develop a reporter 
system for SATB1 repressor function in cell culture.   
To develop an assay system that would depend on introduced SATB1 
constructs, various cell lines were examined to determine their endogenous SATB1 
level (Fig. 6).  Several cell lines, including XC rat fibroblasts, mammary cells of mouse 
and human origin, and the BW5147 CD4+CD8+ mouse T cells were shown to have low 
SATB1 protein expression.  Human breast cancer cells (MCF-7) initially were selected 
for the assay due to their low levels of endogenous SATB1 and their ability to support 
high levels of exogenous SATB1.   
Initially, transient co-transfections were performed in MCF-7 cells with plasmids 
for wild-type SATB1 expression and an MMTV-luciferase reporter. Wild-type SATB1 
suppressed the transiently transfected reporter plasmid up to ca. 10-fold in a dose-
dependent manner (Fig. 12).  Subsequently, various SATB1 mutants were constructed 
to map protein domains important for SATB1 transcriptional activity based on published 
results (Fig. 14) (52,68,149).   Surprisingly the SATB1 mutant ID(346-494), which is 
missing the MAR DNA-binding domain, suppressed MMTV expression to levels similar 
to the wild-type protein (Fig. 16).  Transcriptional repression of the MMTV LTR that is 
independent of DNA binding has been previously reported (39).  Expression of a 
nuclear factor I (NFI-C) mutant, which lacks DNA-binding ability, suppressed MMTV 
 
  117  
expression at wild-type levels, presumably by interference with coactivator function at 
the MMTV promoter (39).  Testing of additional SATB1 mutants revealed that small 
fragments of both N- and C-terminus with no known function also suppressed MMTV 
expression about 4-fold.  These results suggest that SATB1 may suppress MMTV 
expression from unintegrated DNA templates by squelching of general transcription 
factors.  Thus, transient transfection assays do not appear to recapitulate SATB1-
mediated repression of the MMTV LTR observed in vivo.   
Transiently transfected and stably transfected plasmids carrying the MMTV LTR 
have been shown to have different chromatin structures in the nucleus. Binding of 
nuclear factor 1 (NF1) to the DNA, which is required for hormone-dependent chromatin 
remodeling and transcription activation, is distinct for unintegrated and integrated 
templates (83).  NF1 binds constitutively to transiently introduced templates, whereas it 
is excluded from stably integrated templates until hormone treatment (7).  Bovine 
papilloma virus (BPV)-based vectors are episomes that have a chromatin composition 
similar to stably transfected templates (189,200). Therefore, some studies of 
transcription from the MMTV LTR have been performed using BPV-based plasmids 
(36,157).  
MMTV has a hormone-responsive element (HRE) in the LTR, and addition of 
glucocorticoids to virus-infected cells leads to induction of RNA expression by 10 to 50-
fold (174).  A bimodal mechanism has been proposed to explain MMTV promoter 
activation by steroid hormones (7).  In the first step, the binding of ligand-bound 
hormone receptors induces changes in chromatin accessibility and facilitates NF1 
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binding.  In a second step, the nuclear receptor interacts with additional transcription 
factors to recruit them to the promoter and further increase transcription (7).   
Recently, three different forms of stably integrated MMTV promoters have been 
described: the transcriptionally inactive promoter, the basal promoter, and the 
hormone-activated promoter (69).  Transcriptionally inactive promoters contain TBP 
and high levels of histone H1, whereas both the basal promoter and the glucocorticoid-
activated promoter are depleted of histone H1 and contain RNA PolII, TBP, Oct1, and 
acetylated H3 tail domains.  However, only the hormone-activated promoter contains 
stably bound BRG1 (69).  These results and our experiments with transiently 
transfected MMTV LTR-reporter plasmids suggest that integrated transgenes will most 
closely mimick the function of SATB1 on integrated MMTV proviruses. 
Rat fibroblast cells (XC), which express little endogenous SATB1 (Fig. 6), were 
selected to contain stably integrated MMTV LTR-luciferase plasmids.  However, little 
effect was observed after transient transfection of SATB1 expression vectors using 
both lipid transfection protocols and electroporation (184).  This result appears due to 
low transfection efficiency.  Since the majority of the cells have stably integrated 
reporter genes and only a fraction of cells express SATB1, the effects of SATB1 
overexpression could be easily missed because reporter gene activity from 
untransfected cells would mask that of transfected cells.  Therefore, a retroviral 
expression system was adopted to express SATB1 in >90% of the cell population.  The 
retrovirus-based expression assays unequivocally demonstrated that SATB1 
suppresses stably integrated MMTV expression in several different cell types (Figs. 17-
23). 
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These experiments also showed that SATB1 suppresses MMTV expression in 
the absence as well as the presence of the hormone, dexamethasone (DEX), a 
synthetic glucocorticoid (Figs.13 and 21).  Interestingly, transiently transfected and 
stably integrated reporter genes showed different responses to DEX induction in rat XC 
cells.  SATB1 suppressed the transiently transfected reporter gene both in the 
presence and in the absence of DEX (Fig. 13).  However, in stably transfected XC cells, 
SATB1 suppressed the expression of the MMTV reporter gene in the presence, but not 
in the absence, of DEX (Fig.17-20). 
The result that SATB1 suppressed stably transfected MMTV reporter genes 
only in the presence of hormone induction was unexpected.  Therefore, two other cell 
lines, mouse mammary HC11 cells and mouse BW5147 T cells were tested to 
determine whether hormone induction was required for SATB1-mediated suppression 
of the stably transfected reporter gene.  Two cell lines showed that SATB1 represses 
MMTV reporter gene both in the presence and absence of hormone induction (Fig. 21).  
The result observed in XC cells may be cell line-specific for several reasons.  First, 
mice carrying MMTV LTRs with SATB1-binding site mutations showed high reporter 
gene expression in thymus in the absence of hormone induction (124).  CCAAT 
displacement protein (CDP), which has similar protein domains and also binds to the 
MMTV NRE, suppresses MMTV expression both in the presence and absence of 
hormone induction (226).  Finally, knockdown of SATB1 expression in Jurkat cells, 
which express high endogenous SATB1, showed elevation of MMTV expression in the 
absence of glucocorticoid induction (Fig. 24).   
 
  120  
The observation that hormone induction is required for SATB1-mediated 
suppression in XC cells is interesting.  In vivo SATB1 binding to the MMTV promoter 
may increase in the presence of hormone induction in XC cells, and therefore, our 
ability to detect SATB1-mediated suppression may be enhanced.  Transcription factors, 
such as NF1 and Oct1, bind to stably integrated MMTV promoter in the presence of 
hormone induction after the chromatin structure of the stably integrated MMTV gene is 
remodeled by a hormone-nuclear receptor complex (7,69).  This result suggests that 
chromatin immunoprecipitation (ChIP) using SATB1 antibody would precipitate more 
MMTV fragments in the presence of hormone induction.  Additionally, restriction 
enzyme accessibility assays (65) should reveal a relaxed chromatin structure on the 
SATB1 binding sites after hormone induction.  Therefore, ChIP experiments and 
restriction enzyme accessibility assays may clarify the relationship between SATB1-
mediated suppression and MMTV chromatin structure in XC cells and other cell lines. 
Why then does SATB1, a repressor, bind to the MMTV LTR when the promoter 
is activated by a hormone-receptor complex?  This dilemma can be explained through 
an understanding of the tissue distribution of SATB1 and the MMTV life cycle.  SATB1 
is primarily expressed in the thymus (53), with little expression in other tissues, 
including mammary glands.  Milk-borne MMTV infects B- and T-lymphocytes, which 
then deliver the virus to the mammary gland, the final destination.  Despite the early 
infection of lymphoid cells with MMTV, the virus induces breast cancer, not lymphomas.  
However, MMTV variants that cause thymic lymphomas contain a 300-500 bp deletion 
in LTR U3 region (225), which binds at least two cellular proteins, SATB1 and CDP.  
Since CDP is ubiquitously expressed, SATB1 is a good candidate for the suppression 
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of MMTV expression in T cells to prevent the development of lymphomas.  In support 
of this idea, as previously mentioned, mutation of a strong SATB1-binding site in the 
MMTV LTR elevated transgene expression in lymphoid tissues relative to mammary 
tissues (124).   
Hormones have been shown to influence the development of mammary tumors 
in female mice.  Tumor incidence is dramatically increased by hormonal stimulation in 
BALB/c mice infected by foster nursing on MMTV-infected C3H mothers (135).  
Mammary tumor incidence and onset dates also were increased by hormonal 
stimulation in the RIII strain (191).  The increased mammary tumor incidence and/or 
the decrease in the mean latent period for tumor development by hormonal stimulation 
is observed in most of strains of mice (135,191).   
MMTV is well adapted to spread vertically from infected mice to progeny.  The 
virus initially infects lymphocytes, which then deliver virus to mammary glands.  The 
viral production is suppressed in the mammary glands until the mice nurse their pups, 
thus achieving maximal virus concentration in the milk during lactation.  Lymphoma 
development prior to nursing the pups would be disadvantageous for vertical 
transmission of the virus.  MMTV does not encode an oncogene and induces tumors 
by insertional activation of oncogenes.  Random insertional mutagenesis is increased 
by hormone induction of MMTV transcription, resulting in mammary tumors.  Therefore, 
MMTV may not cause lymphomas until transcription levels are sufficiently elevated by 
hormone induction.  Increased transcriptional levels also result in multiple rounds of 
reverse transcription, which produce mutations in the MMTV genome.  Some of these 
mutations lead to the appearance of altered enhancer sequences within the LTR.   
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Insertion of a T-cell specific enhancer into MMTV LTR dramatically increased 
transcription of a reporter gene in transient assays.  However, deletion of the NRE from 
the MMTV LTR marginally increased reporter gene activity in these assays (137).  
Substitution of U3 sequences from the MMTV LTR with those from TBLV, a 
lymphomagenic variant, resulted in viruses that induced exclusively T-cell lymphomas 
(137,213).  Similarly, the contribution of NRE deletion and T-cell enhancers for tumor 
development was tested by injections into mice of cells expressing MMTV proviruses 
with an NRE deletion or insertions of a T-cell specific enhancer (20).  Proviruses with 
the NRE deletion alone induced sporadic mammary tumors, whereas MMTV 
proviruses carrying a T-cell enhancer upstream of the NRE developed both T-cell 
lymphomas and mammary tumors.   Interestingly, Southern blot analysis of DNA 
extracted from lymphomas, but not mammary tumors, revealed loss of the NRE from 
integrated MMTV proviruses (20).  These results suggest that acquisition of a T-cell 
specific enhancer and loss of the NRE with its SATB1-binding sites both are necessary 
for MMTV induction of T-cell lymphomas (20).  
CDP also has been shown to bind the MMTV NRE and is expressed in the 
thymus (124).  CDP suppressed co-transfected MMTV reporter gene activity in a dose-
dependent manner, and CDP-binding site mutations in the MMTV LTR relieved this 
suppression (227).  Furthermore, CDP suppressed MMTV expression in the absence 
as well as in the presence of hormone induction (226).  Although both SATB1 and CDP 
reduce MMTV expression in the presence of hormones (226), glucocorticoids result in 
10- to 50-fold activation of viral transcription.  Thus, the combined action of the two 
 
  123  
suppressors may be required to reduce hormone-activated MMTV expression in 
lymphocytes.   
A 150kD truncated CDP appears in lactating mammary glands of mice, and the 
truncated form does not bind to the MMTV NRE (227).  Therefore, MMTV expression is 
maximal in the mammary glands during lactation during glucocorticoid induction after 
this repressor loses its function.  It would be interesting to determine if CDP or SATB1 
truncation also occurs in the thymus during T-cell development to allow higher MMTV 
transcription after lymphoid differentiation.   
SATB1 may be a key regulator to suppress hormone-induced MMTV 
expression in lymphocytes.  If this is the case, SATB1-null mice (5) should develop 
lymphomas as well as mammary tumors when the null mice are infected with MMTV.  
However, since SATB1-null mice die within 3 weeks of age, this experiment is not 
feasible (5).  SATB1 suppresses MMTV expression in a dose-dependent manner (Fig. 
12 and 18).  Therefore, heterozygous mice, which have half the normal levels of 
SATB1 in thymi, might be used for this experiment (5).  The SATB1-heterozygous mice 
may develop T-cell lymphoma due to high levels of MMTV insertional mutagenesis in 
the thymus more frequently than wild-type littermates. On the other hand, 
tumorigenesis by TBLV, which lacks SATB1-binding sites in the LTR, should be 
unaffected in SATB1 heterozygotes. 
What is the molecular mechanism involved in the suppression of hormone-
induced MMTV expression by SATB1?  It was recently reported that SATB1 binds to 
p300 (66) and the p300-SATB1 complex appears to bind to the MMTV NREs (184).  
CBP and p300 are transcriptional co-activator proteins that act as transcriptional 
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bridges and scaffolds (35).  Thereby, they mediate interactions between DNA-binding 
transcription factors and components of the basal transcription machinery (96). 
CBP/p300 binding to nuclear receptors is necessary for receptor function (45,100) 
perhaps providing a clue to the mechanism for repression of hormone-induced MMTV 
expression by SATB1.  
The integrated MMTV promoter is organized as a phased array of six 
nucleosomes (Fig. 3), which interferes with NF1 and OTF1 binding.  One model 
predicts that SATB1 binding to the MMTV NRE increases following hormone induction 
(Fig. 44).  Once nuclear hormone receptor binds to the HRE, GR recruits the BRG1 
complex and activators such as p300/CBP (82).  The BRG1 complex then alters MMTV 
promoter structure so that H1 dissociates from the promoter, and NF1 and OTF1 are 
recruited.  SATB1 binding to the promoter also increases, thus leading to additional 
interactions with p300 (Fig. 44) and fewer interactions with other transcription factors, 
including ligand-bound hormone receptor.   
In this model, the overexpression of p300 or GR would abrogate suppression 
by SATB1 of the MMTV promoter.  Indeed, overexpression of GR or p300 alleviates 
NF1-C-mediated repression of MMTV in the presence of hormone induction in HeLa 
cells (39).  As the model predicts, CBP/p300 is present in limited concentrations inside 
the cells (86,165).  In agreement with this observation, the Rubinstein-Taybi syndrome, 
results in severe developmental abnormalities from the loss of a single CBP allele 
(165).  Further demonstration of the key role of CBP/p300 involve the ability of 
interferon-α to inhibit TNFα-stimulated HIV expression.  This inhibition is achieved by 
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the competition between STAT-2, which is stimulated by IFN-α and RelA, and TNFα for 


















Fig. 44. Model for SATB1-mediated repression of glucocorticoid-induced 
transcription from the MMTV LTR. 
(A) The integrated MMTV LTR is organized as a phased array of six 
nucleosomes.  SATB1-binding sites in the NRE are tightly arranged by Nuc-C, limiting 
SATB1 binding to the promoter.  (B) When glucocorticoid receptor binds to DEX, the 
complex enters into the nucleus and binds to Nuc-B, resulting in chromatin remodeling 
by the BRG1 complex.  NF1 and OTF1 are recruited, and the binding of general 
transcription factors, activators, and RNA pol II is stabilized, resulting in increased 
MMTV transcription.  Additionally, the efficiency of SATB1 binding to Nuc-C is 
increased by ligand-bound GR, allowing greater SATB1 interactions with p300 and 
fewer interactions with GTFs and/or the BRG1 complex.  Abbreviations: Histone 1 (H1), 
Nucleosome B, C-(Nuc-B, C), dexamethasone (DEX), Glucocorticoid receptor (GR), 
Nuclear factor I (NF1), OTFs (Octamer transcription factors), BRG1 (Brahma-related 
gene 1), General transcription factors (GTFs), and RNA polymerase II (RNA pol II).  
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4.2. MAPPING AND FUNCTION OF SATB1 NUCLEAR MATRIX TARGETING 
SEQUENCE  
SATB1 was originally identified as a thymus-specific transcription factor that 
bound to DNA associated with the nuclear matrix (i.e., MARs) (53).  The nuclear matrix 
is the residual nuclear structure remaining after extensive extraction using treatments 
with a detergent, DNase, and high salt.  The nuclear matrix serves as an attachment 
site to form loop structures of chromatin and plays a pivotal role in nuclear metabolism, 
e.g., DNA replication, transcription, and splicing.  A nuclear matrix targeting sequence 
(NMTS) is responsible for association of proteins with the nuclear matrix.  Sequences 
mediating nuclear matrix association have been determined in a number of proteins, 
including AML-1B, regulator of G protein signaling (RGS12TS-S), Runx2/Cbfa1, human 
nuclear protein NXP-2, the C-terminal domain of Ying Yang 1 (YY1), human 
glucocorticoid receptor, and human androgen receptor (29,37,106,134,205,220,223).  
In addition, the structure of an AML-1 NMTS of 31 amino acids was determined by X-
ray crystallography and consisted of two loops connected by a flexible U-shaped 
peptide chain (197).   
Since SATB1 associates with the nuclear matrix (50), a series of SATB1 
deletion mutations were constructed to delineate the NMTS (Fig. 14).  Using 
biochemical fractionation of transiently transfected cells, an NMTS was mapped to the 
55 amino acids between the dimerization and MAR domains (residues 224 to 278) (Fig. 
29).  An internal deletion mutant of SATB1 lacking the NMTS [∆NMTS or ID(224-278)] 
significantly reduced nuclear matrix association.  However, since this deletion did not 
completely abolish the association, SATB1 may have more than one domain that 
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specifies matrix binding.  Specifically, ID(346-494), a SATB1 mutant missing the MAR-
binding domain, also significantly reduced nuclear matrix association, suggesting 
another NMTS in the DNA binding domain (Fig. 29).  However, this mutant did not bind 
to the MMTV LTR, preventing separation of the functional effects of DNA binding and 
nuclear matrix binding on MMTV transcription.  Therefore, the NMTS within the ID(346-
494) mutant was not studied further.  Nevertheless, fusions of the NMTS(346-494) to 
the GAL4 DNA-binding domain could be used to measure the effects of nuclear matrix 
binding with a GAL4-responsive reporter vector (37).   
The presence of multiple NMTSs has been observed in steroid hormone 
receptors, AML1/ETO, ETO, and YY1 (12).  The results of SATB1 mutant localization 
experiments are consistent with the idea that different proteins may act as receptors for 
directing proteins to specific subnuclear domains.  For example, the nuclear protein 
RGS12TS-S has different targeting sequences for the nuclear matrix and subnuclear 
dots (37).  Lamin B, a known component of the nuclear matrix, clearly has a different 
nuclear distribution than SATB1 (Fig. 27). Moreover, the SATB1 NMTS(224-278) 
showed minimal sequence homology with the NMTS of Runx family proteins (Fig. 45).  
Thus, there may be separate subdomains within the nuclear matrix, which may explain 
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Fig. 45. Alignment of the nuclear matrix targeting sequence of SATB1 and mouse 
Runx family proteins.  
Amino acids sequence alignments of the NMTSs of mouse Runx family proteins 
(220) and SATB1 were performed using CLUSTALW and graphically delineated using 
the GeneDoc software.  The numbers at the right side indicate the number of amino 
acids.  Amino acids are highlighted with black (a fully conserved residue), dark gray (a 
strongly conserved residue), and light gray (a weakly conserved residue). 
 
   
The presence of an NMTS within the SATB1 N-terminus was confirmed by 
tethering amino acids 224 to 278 to either Lex A or GFP, which do not normally bind 
the nuclear matrix.  Both GFP-NMTS and LexA-NMTS partially relocalized to the 
nuclear matrix (Fig. 31).  Interestingly, the SATB1 NMTS also partially redirected GFP 
to the chromatin fraction.  This result may indicate that the 55 amino acids designated 
as the SATB1 NMTS could be further delimited to give either nuclear matrix or 
chromatin binding.  In addition, the SATB1 mutant (1-494) containing the PDZ 
dimerization domain, the NMTS, and the MAR-binding domain localized entirely to the 
chromatin and nuclear matrix fractions, whereas SATB1(1-224) containing only the 
PDZ domain was exclusive to the soluble nuclear fraction (Fig. 29).  SATB1 localization 
to both fractions decreased after deletion of all or part of the MAR domain in various 
mutants (Fig. 29).  Although localization in the soluble fraction may indicate the lack of 
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specific intranuclear trafficking signals, it is also possible that the presence of both the 
MAR and NMTS domains increases the affinity for both the nuclear matrix and 
chromatin.  Previous data have shown that GR association with the nuclear matrix is 
increased by the presence of the GR DNA-binding domain (199).  SATB1 domains 
present at the N-terminus or C-terminus may regulate both chromatin and nuclear 
matrix association. 
The nuclear matrix, a subnuclear domain, plays an important role in 
transcriptional regulation (40,209).  Therefore, the effect of nuclear matrix association 
on the ability of SATB1 to repress MMTV transcription was determined.  Deletion of the 
NMTS(224-278) relieved SATB1-mediated repression of transcription from integrated 
MMTV proviruses or MMTV-LTR reporter plasmids (Figs. 35-38), but there was no 
detectable effect using transiently transfected plasmids containing the MMTV LTR (Fig. 
16).  These observations are reminiscent of the results of Kohwi-Shigematsu et al. in 
which SATB1 suppressed the expression of stably transfected, but not transiently 
transfected, MAR constructs (111).  Although reduced suppression by ∆NMTS [also 
known as ID(224-278)] may be due to conformational changes within the protein, this 
mutant maintained several functional properties, including nuclear import and DNA 
binding (Figs. 25 and Data not shown).  Partial relief of suppression after NMTS 
deletion might result from the retention of other nuclear matrix association sequences.  
Repression by SATB1 and the effect of NMTS(224-278) deletion also were 
independent of the cell type examined since similar results were obtained using mouse 
mammary gland and rat fibroblast cell lines (Figs. 35-38).  Previous data have shown 
that MAR binding to the nuclear matrix is independent of cell type (124,208). 
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Nuclear matrix binding clearly has functional implications for transcription. 
Fractionation studies show that transcriptionally active DNA is tightly associated with 
the nuclear matrix, whereas inactive loci are not.  For example, the ovalbumin gene in 
the chicken oviduct is associated with the nuclear matrix when the gene is stimulated 
by steroid hormones.  However, when the hormone is withdrawn, the gene is detached 
from the nuclear matrix (42).  Genes expressed by integrated polyoma or avian 
sarcoma viruses in transformed cells also were associated with the nuclear matrix, but 
subclones that lack the transformed phenotype and express no detectable viral 
transcripts show little association with the nuclear matrix (46).  Mutations of Pit-1, a 
transcriptional activator of prolactin, altered nuclear matrix localization and led to 
dwarfism in mice (129).  Knock-in mice that express an NMTS-deleted form of Runx2 
have abnormal bone formation and die during embryonic development (40).  The 
Runx2 NMTS autonomously exhibits transactivation in a mammalian one-hybrid 
system (220), whereas deletion of the Runx2 NMTS abrogated the transactivation 
effect on the bone-specific promoters, osteocalcin and transforming growth factor β R1 
(40,187,220).  An NMTS-deletion mutant of Hic-5/ARA55, a GR coactivator, 
maintained its GR-binding ability in yeast cells, but did not fully activate a 
glucocorticoid-responsive promoter (78).  NMTS deletion from transcription regulators 
also affects repression of certain promoters.  RGS12TS-S inhibits transcription in situ 
and in a mammalian one-hybrid assay, and NMTS deletion relieved this suppression 
(37).  Removal of the Runx2 NMTS abrogated repression of the bone sialoprotein 
promoter (40).  Therefore, the nuclear matrix affects gene activation as well as 
repression. 
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SATB1 suppressed integrated reporter gene expression in the presence and 
absence of ligand-bound GR (Fig. 38).  GR functions by recruitment of co-activators 
that acetylate histones and chromatin remodeling complexes (122), and the 
subsequent chromatin reorganization allows promoter-proximal NF1 and Oct1 binding 
and assembly of the basal transcription machinery (14,148).  Both GR and SATB1 are 
bound to the nuclear matrix (50,199), where there may be competition between 
recruitment of HATs and HDACs. Such competition may explain the partial effect of 
SATB1 overexpression on hormone-induced MMTV expression. NMTS deletion would 
decrease SATB1-mediated HDAC recruitment, which may impede interaction with 
CHRAC, ACF and NURD chromatin remodeling complexes (218).  SATB1 is bound to 
MARs at the bases of chromatin loops (50) and may regulate effects of cis-acting 
regulatory elements in cellular DNA by acting as an insulator (151).  For MMTV, which 
contains MARs at either end of the genome in the LTR (124), insulation from 
surrounding cellular regulatory control after genome insertion may provide repression 
of viral transcription in T cells and a selective advantage for virus survival. 
 SATB1 is known to recruit chromatin remodeling complexes, which contain 
HDAC-1 and -2, to change overall loop structures of chromatin (218).  SATB1 binds to 
the promoters of IL-2 and IL-2Rα and recruits HDAC1, which results in decreased 
levels of transcription (115).  Thus, SATB1 may repress MMTV expression by HDAC 
recruitment to the MMTV LTR.  This hypothesis was tested using a specific HDAC 
inhibitor, trichostatin A (TSA). 
Acetylation of histones has long been correlated with transcriptional activity (4).  
Generally, acetylation of the N-terminal tails of the core histones opens the 
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nucleosome structure and enhances transcription, whereas deacetylation has the 
opposite effect, mediating transcriptional suppression (3,26,99,156).  However, the 
relationship between histone acetylation and transcription is more complicated 
(34,51,180).  For example, in mammalian cells, c-myc and cyclin D1 genes are 
repressed by HDAC inhibitors (112,185).  Interestingly, MMTV transcription was both 
enhanced and reduced by the addition of TSA, depending on the concentration of the 
HDAC inhibitor (13).   
Two different concentrations of TSA were tested to determine whether the 
effect on SATB1-mediated MMTV repression.  Both low and high concentrations of 
TSA suppressed luciferase activity driven by the MMTV promoter in HC11 mammary 
cells (Fig. 39).  However, SATB1 and ∆NMTS [ID(224-278)] nullified TSA-mediated 
repression of MMTV transcription at high concentrations of TSA, while ∆DBD and 
empty vector did not affect MMTV expression (Fig. 39).  These results suggest that 
deletion of nuclear matrix association sequences between amino acids 224 and 278 
has no effect on HDAC association with SATB1. 
A previous report showed that TSA-mediated repression was mediated through 
the TATA box region and was independent of chromatin remodeling and histone 
acetylation.   These results suggest that HDAC inhibitors may affect acetylation of non-
histone proteins (145).  Thus, SATB1 binding to DNA also may determine the function 
of unidentified non-histone proteins in the TATA region of the MMTV LTR.   
It appears likely that the function of the SATB1 NMTS(224-278) is mediated 
through functional interaction with other nuclear proteins.  A yeast two-hybrid screen 
was used to identify proteins that interact with this NMTS in the nuclear matrix (Fig. 40).  
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Two different screens identified about 40 proteins (Table 2) as potential interaction 
partners of NMTS(224-278).  Lamin A, which is one of the major nuclear matrix 
proteins, was identified through the screen and the interaction between lamin A and the 
NMTS was confirmed using co-immunoprecipitation experiments with full-length 
SATB1 and lamin A (Figs. 41 and 42).  However, co-immunoprecipitation experiments 
with wild-type SATB1 and ∆NMTS showed no significant binding specificity between 
lamin A and the NMTS(224-278) since both wild-type SATB1 and ∆NMTS interact with 
lamin A in 293T cells (Fig. 43).   
Two major types of lamins are found in most mammalian cells: B-type lamins 
(B1 and B2), which are found in all somatic cells, and A-type lamins (A and C), which 
are expressed primarily in differentiated cells (175,196).  Lamin A was overexpressed 
in XC cells carrying integrated MMTV LTR-reporter plasmids to determine its effect on 
SATB1-mediated repression of viral transcription.  However, neither negative nor 
positive effects on MMTV transcription were observed (184).  Since lymphocytes do 
not usually express A-type lamins, (171,179,184), the interaction between lamin A and 
SATB1 may play a more important role in other tissues, such as brain or testis. 
It is still not clear how nuclear matrix binding regulates SATB1-mediated 
repression of MMTV RNA levels.  However, AML1 and the corepressor mSin3A are 
colocalized in the nuclear matrix when AML1 is not phosphorylated (92).  Upon 
phosphorylation, AML1 translocates from the nuclear matrix, is released from mSin3A, 
and transcriptional activity is enhanced (92).  This phosphorylated form of AML1 is 
subject to proteasome-mediated degradation in a time-dependent manner (92).  
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SATB1 also has been reported to be phosphorylated, although direct evidence for this 
modification is lacking (68).    
Recently, SATB1 was shown to be sumoylated (72).  SUMO modification is 
known to regulate activity and/or nuclear and subnuclear localization of many proteins, 
including Sp3, RanGAP, and PML (71,131,176,224).  Therefore, the activity and/or 
nuclear matrix localization of SATB1 may be modulated by sumoylation.  Identification 
of proteins that interact with SATB1 in the nuclear matrix as well as SATB1 
modifications that influence protein-protein interactions should enhance our 
understanding of the mechanisms by which SATB1 binding to the nuclear matrix 
regulates MMTV expression.  In addition, these studies should illuminate the larger 
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APPENDIX 
 
List of abbreviations used: 
ACF   ATP-utilizing chromatin assembly and remodeling factorY 
AML  acute monocytic leukemia 
BRG1  Brahma-related gene 1 
Bright  B cell regulator of IgH transcription 
BURs  base-unpairing regions 
CAT  chloramphenicol acetyltransferase 
CBP  CREB-binding protein 
CDP   CCAAT-displacement protein 
CH  Chromatin fraction 
ChIP  chromatin immunoprecipitation 
CHRAC  chromatin-accessibility complex  
CR  Cut-like repeats 
CREB  cAMP responsive element binding protein 
DAPI   4’,6-diamidino-2-phenylindole  
DBD   DNA-binding domain  
DEX   dexamethasone  
DMEM  Dulbecco’s modified Eagle’s medium  
DOX   doxycycline 
DRIP  vitamin-D-receptor interacting protein 
EGF  epidermal growth factor 
EMSA  electrophoretic mobility shift assay  
Env  envelope protein 
FACS   fluorescence-activated cell sorter  
FITC  fluoresceinisothiocyanate 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase  
GFP  green fluorescent protein  
GR   glucocorticoid receptor  
GTFs  general transcription factors 
HAT   histone acetyltransferase  
HDAC  histone deacetylase  
HRE   hormone responsive element  
HS1  Dnase I-hypersensitive site 1 
ID   internal deletion  
IgH  immunoglobulin heavy chain 
IL-2Rα,  interleukin-2 receptor alpha  
IN  integrase 
IRES   internal ribosomal entry site  
LTR   long terminal repeat  
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MAR   nuclear matrix-associated region  
MARs  matrix attachment reagions 
MBR   major breakpoint region 
MMTV  mouse mammary tumor virus 
MOI  multiplicity of infection 
MTVR  MMTV receptor 
NBP  NRE-binding protein 
NF1  nuclear factor 1 
NLS   nuclear localization signal  
NM  nuclear matrix fraction 
NMTS   nuclear matrix targeting sequence  
NRE   negative regulatory element 
Nuc  nucleosome 
NuMA  nuclear-mitotic apparatus protein 
NURD   nucleosome remodeling and deacetylase complex  
Oct 1  octamer-binding protein 1 
P/CAF  p300/CBP-associated factor 
PBS   phosphate-buffered saline  
PBS  primer-binding site 
PMSF   phenylmethylsulfonyl fluoride  
RGS12TS-S regulator of G protein signaling 
RNP  ribonucleoprotein 
RNP pol II RNA ploymerase II 
RPA   ribonuclease protection assay  
RPMI  Roswell park memorial institute 
RT  reverse transcription 
SA  splice acceptor 
Sag  superantigen 
SATB1   special AT-rich binding protein 1 
SD  splice donor 
SF  soluble fraction 
siRNA   small interfering RNA. 
SnRNP small nuclear ribonucleoproteins 
SRC  steroid receptor coactivator 
STAT  signal transducers and activators of transcription 
SUMO  small ubiquitin-related modifier 
TBP  TATA-binding protein 
TCR  T-cell receptor 
Tfrc  transferrin receptor 
TM   transmembrane 
TNFα  tumor necrosis factor α 
TRAP  thyroid hormone receptor-associated protein 
TSA  trichostatin A 
UBP  upper or ubiquitous-binding protein 
WL  whole cell lysate 
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